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Precis: Patients with Fanconi’s Anemia (FA) are at increased risk of head and neck squamous 
cell carcinoma (HNSCC), but the prevalence of undiagnosed FA patients with HNSCC is 
unknown. Targeted germline sequencing of 417 patients with HNSCC identified several known 
FA variant mutations and several novel FA mutations; although no patients with HNSCC were 
found to have clinical signs of FA, FA mutations in HNSCC may explain a potential mechanism 
for tumorigenesis.   
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ABSTRACT  
Background: Patients with Fanconi anemia (FA) have increased risk for head and neck 
squamous cell carcinoma (HNSCC). We sought to determine the prevalence of undiagnosed FA 
and FA carriers in patients with HNSCC and an age cutoff for FA genetic screening. 
 
Methods: Germline DNA from 417 HNSCC patients under age 50 was screened for sequence 
variants by targeted next-gen sequencing of the entire length of 16 FA genes.  
 
Results: The sequence revealed 194 FA gene variants in 185 patients (44%). The variant 
spectrum was comprised of 183 nonsynonymous point mutations, nine indels, one large 
deletion, and one synonymous variant predicted to effect splicing. 108 patients (26%) had at 
least one rare variant predicted to be damaging, and 57 (14%) had at least one rare variant 
predicted to be damaging and previously reported. Fifteen patients carried two rare variants, or 
an X-linked variant, in an FA gene. Overall, we did not identify an age cutoff for FA screening 
among young HNSCC patients, as there were no significant differences in mutation rates when 
patients were stratified by age, tumor site, ethnicity, smoking status, or human papillomavirus 
status. However, we observed an increased burden, or mutation load, of FA gene variants in 
FANCD2, FANCE, and FANCL in our HNSCC patient cohort relative to the 1000 Genomes 
population. 
 
Conclusions: FA germline functional variants offer a novel area of study in HNSCC 
Tumorigenesis. FANCE and FANCL, components of the core complex, are known to be 
responsible for the recruitment and ubiquitination, respectively, of FANCD2, a critical step in the 
FA DNA repair pathway. The increased mutation load of FANCD2, FANCE, and FANCL 
variants in our younger HNSCC patient cohort indicates the importance of the FA pathway in 
HNSCC. 
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INTRODUCTION 
Fanconi anemia (FA) is a rare, predominantly recessive inherited disorder with an 
incidence of 1 in 130,000 births and a carrier rate estimated to be 0.6% (1,2). Genetically, FA is 
a heterogeneous disease with 21 causative genes known so far, as five new genes were added 
within the past year (3,4). Phenotypically, FA is associated with congenital defects (short 
stature, renal defects, café au lait spots, microphthalmia, hearing difficulties and abnormal 
thumb or radii) and progressive bone marrow failure. In addition to the congenital anomalies, 
and the inevitable bone marrow failure, FA patients are at increased risk of acute myelogenous 
leukemia and head and neck squamous cell carcinoma (HNSCC) (5,6). However, 30% of 
patients fail to display the FA congenital defects (7,8), and up to 25% present with solid or 
hematological malignancies as the first sign of the condition (9).  In many such instances, FA 
diagnosis is prompted after encountering severe toxicities upon initiating chemotherapy or 
radiation therapy to treat the malignancy (10). The pathogenesis is based on the fact that the 
normal function of FA genes is related to DNA repair and genome stability; bi-allelic mutations of 
these genes confer a 0.7-2% annual risk of cancer (5,9,11), and some, including FANCD1 
(BRCA2) and FANCN (PALB2), are closely associated with solid organ malignancies (12-14) 
Head and neck squamous cell carcinoma is traditionally related to tobacco and alcohol 
consumption and recently associated with human papillomavirus; the risk is a 10 to 15-fold 
increase compared to those without these exposures (15,16). However, FA confers a 500-700-
fold increased risk of HNSCC compared to the normal population (9,17,18). The median age of 
HNSCC onset in FA patients is 33 years compared to 60 years in traditional HNSCC patients; 
thus FA patients develop HNSCC at a significantly younger age than sporadic HNSCC (19).  
Younger HNSCC patients have reduced DNA repair capacity but the prevalence of FA 
mutations in HNSCC patients remains unknown (20). Given 30% of patients with FA mutations 
do not display the congenital stigmata of FA, we sought to determine:  1) the prevalence of 
undiagnosed FA among HNSCC patients younger than 50 years, 2) an age cutoff for FA 
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screening among younger HNSCC patients, and 3) the prevalence of FA carriers (heterozygote 




DNA was isolated from blood using the Puregene kit and DNeasy blood and tissue DNA 
extraction kit (Qiagen), and subjected to phenol/chloroform extraction and ethanol precipitation.  
Samples for sequencing 
Six hundred forty-seven HNSCC patients younger than 50 years were enrolled in a prospective 
molecular epidemiologic study of newly diagnosed HNSCC that included completion of a 
prospective standardized epidemiologic questionnaire and blood draw. Patients with cancer 
(including known FA) prior to HNSCC diagnosis were excluded. The Institutional Review Board 
of the University of Texas MD Anderson Cancer Center approved this study, and all patients 
gave informed consent. 
Of the 617 patients initially enrolled for the study (Supplemental Figure 1), DNA was available 
from 468 patients. DNA from 417/468 patients was of sufficient quality and quantity required for 
the targeted capturing and sequencing approach. Thus, DNA from 417 patients was sequenced. 
There is no difference between the sequenced group (417 patients) and the non-sequenced 
group (230 patients) in terms of age, gender, ethnicity, smoking, and alcohol drinking 
(Supplemental Table 1). There was a higher proportion of Larynx/Hypopharynx among those 
excluded and a higher proportion of Oral cavity in those included. 
Targeted Next-Gen Sequencing 
The genomic regions representing the entire length of 16 FA genes were targeted for capturing 
and sequencing (Supplemental Table 2).  The exceptions were the exon 1 regions of FANCA, 
FANCB, and FANCE, which were not covered by the sequencing approach. Excessive repeat 
sequences prevented the successful design of probes for exon 1 of FANCA. Probes were 
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designed for the FANCB and FANCE exon 1 regions but did not yield product. The targeted 
Truseq (Illumina) capturing design, capture, and sequencing were done as previously described 
(21). 
Variant calling and filtering 
Novoalign (http://www.novocraft.com/products/novoalign/) was used for sequence alignment. 
The MPG (“Most Probably Genotype”) genotype caller 
(https://research.nhgri.nih.gov/software/bam2mpg/; NHGRI Genome Technology Branch) was 
used to call variants, and SnpEff (22) was used to filter the high quality functional variants based 
on the following criteria: quality score ≥ 20, read depth ≥10, nonsense, missense, indel, splicing 
(+/- 2bp). The extracted functional variants were subsequently annotated and filtered using a 
population-specific maximum frequency, where applicable, of .5% in each of the 1000 Genomes 
(2,504 individuals), the NHLBI-ESP6500 (6,503 individuals), and the ExAC-nonTCGA (60,706 
individuals) variant databases. The allele frequency threshold of .5% is derived from the FA 
carrier frequency of 1:181(2). All coordinates are in accord with human genome build 19. 
Predicted damaging variants 
To predict the functional consequence of a variant, we compared the results from five prediction 
algorithms: Sift (http://sift.jcvi.org), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2), 
MutationTaster (http://www.mutationtaster.org/), CADD (http://cadd.gs.washington.edu), and 
GERP++ (http://mendel.stanford.edu/SidowLab/downloads/gerp/).  We used a minimum 
threshold of 20 for Phred-scaled CADD scores, representing the 1% most damaging variants in 
the genome, and a minimum threshold of 2 for GERP++ RS scores. GERP++ was included to 
highlight constrained sites. Annovar (23) was used to annotate the variants with the results from 
all five prediction algorithms. For consideration as “Damaging”, at least 4 of the 5 algorithms had 
to meet their specified threshold. “Benign” variants did not meet the threshold in at least 4 of the 
5 algorithms. Variants lacking consensus between at least 4 algorithms were labeled as 
“Indeterminate” (Figure 1, Supplemental Table 3) 
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Previously reported variants 
The following databases were used to identify previously reported variants: The Leiden Open 
Variation Database (LOVD) for Fanconi anemia (http://www.rockefeller.edu/fanconi/) ClinVar 
NCBI database (http://www.ncbi.nlm.nih.gov/clinvar/), and BIC (Breast Cancer Information 
Core). 
Synonymous variants 
Synonymous variants with quality score ≥ 20 and a read depth ≥ 10 were analyzed using 
SILVA-v1.1.1 (24). Variants determined to be “potentially pathogenic” by SILVA were further 
analyzed by NetGene2 (25) to predict splicing effects. 
SNP array analysis 
The patient DNA samples were run on the Illumina HumanExome Bead Chip, containing 
~250,000 SNPs. The data were processed using GenomeStudio (Illumina, Inc.), and CNVs 
were detected using cnvPartition v3.2 (Illumina, Inc.) and Nexus v7.5 (BioDiscovery, Inc.). 
 
Statistical analysis of mutation load  
The Mann-Whitney-WIlcoxon non-parametric statistical test was used to evaluate the burden or 
mutation load of FA gene variants in the HNSCC patient cohort compared to the 1000 Genomes 
dataset. Given the HNSCC cohort was comprised predominantly of patients with Caucasian 
ethnicity (Table 1A), the statistical test was performed using data from the 356 Caucasian 
HNSCC patients and the 503 EUR 1000 Genomes individuals to create a more homogenous 
comparison group. We obtained the nonsynonymous and indel variant alleles from each set and 
implemented the test in R (26). 
Low frequency variants 
LoFreq (27) was implemented to call low frequency variants occurring between 5 – 40 percent 
with a genotype quality > 500. 
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RESULTS 
Of the 417 patients with DNA available for sequencing, 88 (21%) were younger than 40 
(a traditionally accepted definition of “young” for a patient with HNSCC), 108 (26%) were 40-44, 
and 221 (53%) were 45-49 years of age. Tumor site was oral cavity in 149 (36%), oropharynx in 
230 (55%) and larynx in 38 (9%). The cohort was comprised of four different ethnic populations, 
356 (85%) are Caucasian, 40 (10%) are Hispanic, 14 (3%) are Asian, and 7 (2%) are African 
American (Table 1A). 
No patient in the cohort had a known diagnosis of FA, and there were very few with any 
potential signs of a FA phenotype. Classic phenotypes of FA were then evaluated in the cohort. 
Seventeen patients (4%) had a first-degree relative with a hematologic malignancy, 25 (6%) had 
short stature (<fifth percentile), and eight (2%) had macrocytic anemia and/or leukopenia, and 
among the patients who received chemotherapy, there were no grade IV toxic effects. 
Germline DNA targeted capturing and next-gen sequencing of 16 FA genes revealed 
11,968 initial variants. The targeted region for capturing and sequencing included the entire 
gene. The post sequence coverage of high quality sequence, particularly for the entire coding 
region of 56,120 bp, was 100% for all genes except for a total of 287 bp from the exon 1 of 
FANCA, FANCB and FANCE, with a depth of coverage around 240 reads at each base 
(Supplemental Table 2) (21). 
Among the 11,968 initial called variants, there were 137 synonymous variants and 358 
functional variants (nonsense, missense, indel, or splicing) (Figure 1). Using a population-
specific variant frequency threshold of ≤ .5% in each of 1000 Genomes, NHLBI-ESP6500, and 
ExAC databases, the subset of functional variants was further reduced to 192 (183 SNVs and 9 
indels). Functional prediction algorithms (SIFT, PolyPhen, MutationTaster, CADD, and 
GERP++) analyzed the 183 rare SNVs to identify which may be likely to induce deleterious 
functional consequences and which are likely benign. Assignment of a definitive prediction to a 
particular variant was dependent on at least four of the five algorithms reaching a consensus. If 
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a consensus was not met between at least 4 algorithms, the prediction was classified as 
indeterminate, and labeled as such. 80 rare SNVs were predicted to be damaging and 64 were 
predicted to be benign, while 39 were indeterminate. The 9 indels were presumed to be 
deleterious by the nature of the variant. Splicing prediction algorithms (SILVA and NetGene2) 
analyzed the 137 synonymous variants and identified 1 variant as likely pathogenic by creating 
a new donor site. 
The 193 resulting variants (184 SNVs and 9 indels) were compared to variants that had 
been previously reported to the LOVD Fanconi anemia disease database, BIC (Breast Cancer 
Information Core), and/or listed in ClinVar. Forty-four percent (85/193) of variants had been 
previously reported in at least one of the three databases, but only 5/85 were listed, specifically, 
as pathogenic, while the rest were listed as either benign or uncertain significance. Variants in 
BRCA2 (36) and PALB2 (9) comprised 52% (45/85) of the reported variants. In addition to the 
85 reported variants, our cohort carried 71 variants that were unreported but present at a 
frequency below .5% in the public databases, and 38 completely novel variants. 
In addition to high throughput sequencing of the 16 FA genes, genotype data was 
collected by SNP array, from Illumina’s HumanExome BeadChip, for all 417 HNSCC patients. 
Copy number analysis revealed a ~154kb heterozygous deletion of SLX4, spanning the entire 
gene, in a HNSCC patient. This patient also carried a SLX4 missense mutation that was 
predicted to be damaging (Table 2). 
We also implemented LoFreq to call low frequency variants occurring between 5%-40% 
with a quality score greater than 500 and a minor allele frequency less than .5% in public 
databases. It is known that revertant mosaicism in Fanconi anemia may result in the loss of a 
variant, or a variant being present to a lower extent, and in such cases cancer may precede the 
diagnosis of FA (28). However, our search for low frequency variants did not yield any potential 
candidates. 
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Of the 417 patients, 185 (44%) carried at least one rare variant (Table 1B). The 185 
patients carried 194 variations (192 rare variants, a large deletion, and a synonymous variant 
that was predicted to affect splicing).  A rare variant was observed in 42%-55% of patients from 
Caucasian, Hispanic, and African American ancestry, whereas 79% (11/14) of Asian patients 
carried a variant. A rare variant was seen in a similar proportion of patients irrespective of tumor 
site, Larynx (42%), Oral Cavity (44%) or Oropharynx (45%), or age group, < 40 (40%), 40-44 
(49%), or 45-49 (44%) years (Table 1B,1D). The proportion of patients carrying rare predicted 
damaging variants was also similar irrespective of tumor site, 25%-28%, or age group, 24%-
28% (Table 1C-D). 
Fifteen patients (4%) had either two rare FA variants in the same FA gene or an X-linked 
variant of FA (Table 2).  Among these 15 patients, the median age was 45 years (only 2 were 
<40 years), 10 (67%) had oropharyngeal primary tumors, 8 (47%) were never smokers, 2 (13%) 
had a first-degree relative with a hematologic malignancy, 5 (33%) had short stature (<fifth 
percentile), and 3 (20%) had macrocytic anemia and/or leukopenia. Relative to the entire cohort, 
there were no differences in age, sex, smoking status, tumor site, or human papillomavirus 
status between patients carrying two rare variants in the same FA gene or an X-linked FA 
variant or not. Of the 15 patients with two rare variants, or an X-linked variant, six carried 
variants that had been previously documented in either the FA mutation database, ClinVar, or 
BIC. 
Thirty-nine patients carried a rare variant in two or more different FA genes 
(Supplemental Table 4). When comparing age at presentation of patients with and without 
multiple variants, there was no difference in age, sex, smoking, alcohol use, or HPV 
status. 
The 194 germline variations were comprised of 176 missense, 9 indels, 6 nonsense 
(including one stoploss), 2 splicing (including one synonymous), and 1 large deletion (Figure 2, 
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Supplemental Table 3). These variants amounted to 255 occurrences throughout the HNSCC 
cohort (Table 3). BRCA2, FANCP, FANCM, FANCA, and FANCI were the most common genes 
to carry rare variants (21% (54/255), 14% (36/255), 11% (27/255), 9% (22/255), and 8% 
(20/255), respectively).  Twenty-six percent of patients (108/417) carried 91 FA rare variants 
predicted to be damaging, where BRCA2 had the highest proportion of occurrences at 10% 
(25/255), and SLX4, FANCI, FANCM, FANCQ, each accounted for 5% (12-14/255). Fourteen 
percent of patients (57/417) had rare variants predicted to be damaging and previously 
reported. BRCA2 with 10% (25/255), and SLX4 and FANCQ each with 3% (7-8/255) are the top 
three most prevalent carriers. Detailed characterization of each of the 194 rare variants is 
presented in Supplemental Table 3. 
Table 4 presents the incidence of rare variants, by FA gene, among the HNSCC cohort, 
segregated by tumor site, ethnicity, and age group. There were no significant differences in 
mutation rates when patients were stratified by age, tumor site, ethnicity, smoking status, or 
human papillomavirus status.  
Finally, we looked for an increased burden or mutation load of FA gene variants in our 
cohort in comparison to the 1000 Genomes dataset using the Mann-Whitney-Wilcoxon 
nonparametric test. Because our cohort is comprised, predominantly, of patients with Caucasian 
ethnicity, the statistical comparison was between the 356 Caucasian HNSCC patients and the 
503 individuals of European ancestry in the 1000 Genomes dataset. This comparison revealed 
that FANCD2, FANCE, and FANCL had a significantly increased burden in our cohort (Table 5). 
At the same time, the mutation burden for BRCA2, FANCG, and FANCQ was significantly 
reduced in our cohort.  
 
DISCUSSION 
Though HNSCC is highly associated with FA, the prevalence of FA germline variants in 
younger HNSCC populations has not been explored. While the primary purpose of this study 
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was to define an age cutoff among patients with HNSCC to undergo genetic screening for FA, 
there was no correlation of younger age with FA germline variants. In a previously reported 
tumor genomic analysis of HNSCC in low-risk patients (nonsmokers <45 years old) and 
traditional high-risk patients (smokers >45 years old), age was not a marker of genome 
instability: rates of gene-specific mutations and copy-number alterations were similar in oral 
tongue cancers in low-risk patients and oral tongue cancers in traditional high-risk patients (29). 
Similarly, we did not see a difference in prevalence of FA germline mutations between patients 
younger than 40, 40-44, and 45-50 years of age or between smokers and nonsmokers. 
Our patient cohort consisted of four different ethnicities, so it was important to use an 
approach that involved population-specific frequencies to ensure that low frequency variants 
were properly characterized. 185 patients carried 194 total variations, including 183 rare 
nonsynonymous variants, a synonymous variant predicted to affect splicing, 9 indels, and a 
large deletion (Figure 1). 108 patients carried at least one variant predicted to be damaging. We 
identified 38 novel FA germline variants, including a synonymous variant and a large deletion, 
not present in control populations or previously documented in disease-associated databases, 
23 (61%) of which were predicted to be damaging (Figure 1, Supplemental Table 3). There were 
15 patients carrying two rare alleles in the same FA gene, which included three that were known 
to have anemia and/or leukopenia and two presenting with short stature. FA germline variants, 
and genome instability, may play a broader role in HNSCC susceptibility regardless of age or 
traditional risk factors. 
Mutations in the FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, 
FANCL, FANCM, and the recently identified FANCT) affect ubiquitination of the FANCD2/FANCI 
complex, a critical step in the FA pathway that repairs DNA damage and maintains genomic 
stability (5,30). FANCL is a member of the FA core complex with E3 ligase enzymatic activity for 
FANCD2 mono-ubiquitination (31). FANCE recruits FANCD2 to the FA core complex for 
ubiquitination, and subsequent DNA repair (32). Interestingly, FANCD2, FANCL, and FANCE 
Page 14 of 79Cancer












  11/21/2016 
homologs form a subset of the FA genes present in Ciona intestinalis, thought to be the closest 
invertebrate relative of vertebrates (33,34), and thus appear to be an evolutionarily conserved 
part of the FA pathway. It is likely that mutations affecting FANCD2, FANCE, or FANCL modify 
cancer susceptibility through altered DNA repair and genomic instability. In the current study, we 
observed an increased burden, or mutation load, of variants in FANCD2, FANCL, and FANCE in 
HNSCC patients compared to population-level estimates (Table 5). One would expect that FA 
patients with mutations in FANCD2, FANCL, and FANCE may be predisposed to developing 
HNSCC. However, it is not practical to evaluate this from clinical experience of FA patients, as 
FANCL, FANCE, and FANCD2 patients represent only 0.4%, 1% and 4% of all FA patients (4), 
respectively, and may often succumb to other maladies, not surviving long enough to develop 
HNSCC.  Recently, missense mutations in the FANCD2/FANCI complex have been associated 
with colorectal carcinoma (35). The FA pathway, FANCD2 in particular, is implicated in 
facilitating replication through common fragile sites (36), a critical process in maintaining 
genomic stability.  Interestingly, a study reporting results from sequencing 190 patients with 
esophageal squamous cell carcinoma (ESCC) for germ line variants in 12 FA genes identified 
heterozygous indel variants, one each, in FANCD2, FANCE, and FANCL in three patients, each 
with a strong family history of ESCC (37). ESCC and squamous cell carcinoma of the anogenital 
tract, in addition to HNSCC, form the cancer spectrum displayed in FA patients (17). Germline 
mutations in FANCD2, FANCE, and FANCL may provide a novel area of study for HNSCC 
susceptibility and tumorigenesis. 
In conclusion, our analysis of FA gene germline variations in 417 HNSCC patients under 
the age of 50 identified 15 patients carrying two variants in an FA gene, five of whom presented 
with a FA-associated phenotype, but we did not identify a specific age cut-off for FA screening. 
We identified 44% (185/417) of the patients in our cohort as heterozygous carriers of a rare FA 
gene variant, and variants in 60% of these patients (108/185) were predicted to be damaging. In 
addition, the increased mutation burden of FANCE, FANCL and FANCD2, key players in the 
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FIGURE LEGENDS 
Figure 1. Schematics of FA gene variant analysis in HNSCC patients. Data from SNP array 
were analyzed for copy number variations. SNV discovery was performed from targeted 
sequencing of 16 FA genes. Synonymous variants were analyzed for splicing effects. Indels, 
nonsynonymous, and splicing variants were screened for quality and filtered using population-
specific frequencies, where applicable. The resulting rare variants were screened for presence 
in the FA mutation database (FAmutDB) and ClinVar, and analyzed by functional prediction 
algorithms to determine potential pathogenicity. 
^ Unreported variants were present at a frequency below .5% in the public databases but not 
reported to the FA mutation database, ClinVar, or BIC. 
* Novel variants were not present at any frequency in the public databases used for filtering. 
 
Figure 2. The 194 rare variants, by mutation type, observed in the 16 FA genes from 
185/417 HNSCC patients 
The plot shows the number and type of rare variants observed in each FA gene along with the 
number of rare variants that were predicted to be damaging. ^includes one stoploss; *includes 
one synonymous variant 
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Table 1: Distribution of patients by age, sex, ethnicity, and primary tumor site, as well as by 
prevalence of FA gene variants. 
A. 417 HNSCC Patients, segregated by cancer site, age group, and ethnicity 
 
Oral Cavity (n=149) Oropharynx (n=230) Larynx (n=38)   
Total <40 40-44 45-49 <40 40-44 45-49 <40 40-44 45-49 
Caucasian 40 32 45 23 54 129 3 9 21 356 
African American 0 0 2 0 1 1 1 0 2 7 
Hispanic 8 4 8 7 5 7 0 0 1 40 
Asian 3 4 3 1 0 2 0 0 1 14 
Total 51 40 58 31 60 139 4 9 25 417 
 
B.   185 HNSCC Patients Carrying a Rare FA Gene Variant 
 
Oral Cavity (n=66) Oropharynx (n=103) Larynx (n=16)   
Total % <40 40-44 45-49 <40 40-44 45-49 <40 40-44 45-49 
Caucasian 16 11 22 4 29 55 2 4 6 149 42 
African American 0 0 0 0 0 0 1 0 2 3 43 
Hispanic 5 3 2 4 3 5 0 0 0 22 55 
Asian 1 3 3 1 0 2 0 0 1 11 79 
Total 22 17 27 9 32 62 3 4 9 185  
Percent (%) 45 42 44  
 
C.   108 HNSCC Patients Carrying a Rare Predicted Damaging FA Gene Variant 
 
Oral Cavity (n=41) Oropharynx (n=57) Larynx (n=10) 
Total % <40 40-44 45-49 <40 40-44 45-49 <40 40-44 45-49 
Caucasian 10 7 13 1 15 32 2 1 4 85 24 
African American 0 0 0 0 0 0 0 0 2 2 29 
Hispanic 4 3 0 3 3 2 0 0 0 15 38 
Asian 1 2 1 0 0 1 0 0 1 6 43 
Total 15 12 14 4 18 35 2 1 7 108  
Percent (%) 28 25 26 
 
D.   Percentage of HNSCC Patients Carrying Rare variants, and Rare Predicted Damaging variants, 





PATIENTS CARRYING A RARE 
VARIANT (%) 
PATIENTS CARRYING A PREDICTED 
DAMAGING RARE VARIANT 
< 40 86 34 (40) 21 (24) 
40-44 109 53 (49) 31 (28) 
45-49 222 98 (44) 56 (25) 
TOTAL 417 185 (44) 108 (26) 
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Table 2. Patients carrying two variants in one Fanconi anemia (FA) gene or an X-linked variant of FA 









Mutation 1 Mutation 2 









A5421β C M 46 OP None Never Positive BRCA2 c.1792A>G p.T598A Yes Benign c.1804G>A p.G602R Yes Benign 
A5809 C F 45 OP None MD Positive BRCA2 c.8573A>G p.Q2858R Yes Damaging c.1151C>T p.S384F Yes Damaging 
A1105 C M 44 OP None Never MD ERCC4 c.1336G>T p.A446S -- Indeterminate c.1347C>A p.V449V^ -- Damaging 
A4798 C M 42 OP None Current Positive FANCA c.1046C>T p.A349V -- Indeterminate c.2390C>T p.A797V -- Benign 




c.30C>A p.N10K -- Benign -- -- -- -- 
A2766 H M 31 OC None Never MD FANCI c.868G>A p.V290M -- Benign c.1114G>A p.V372I -- Indeterminate 
A3494 H M 47 OP A Never MD FANCI c.3493delG p.D1105fs Yes Damaging c.3946G>A p.G1316R -- Benign 
A4164 C M 49 OC None Never MD FANCI c.1461T>A p.Y487X Yes Damaging c.362T>C p.L121P -- Damaging 
A4741 C F 33 OC None Former MD FANCM c.5117A>C p.N1706T -- Benign c.3827C>T p.S1276L -- Benign 
A2217 C M 46 OP L & A Current MD SLX4 c.3739G>A p.E1247K -- Damaging c.833G>A p.R278Q -- Benign 
A2281 C M 43 OP None Former MD SLX4 c.2182G>A p.A728T -- Damaging c.5281C>T p.R1761C -- Damaging 
A3094 C F 43 OC Ht Current Positive SLX4 c.4264C>G p.P1422A -- Indeterminate c.2364G>C p.Q788H -- Benign 
A4325 C F 49 OP None Never MD SLX4 c.3368C>A p.S1123Y Yes Damaging Large deletion
‡
 -- -- Damaging 
A5423 H M 47 OP None Former Positive SLX4 c.4261A>T p.I1421F Yes Indeterminate c.2290C>G p.P764A -- Benign 
A2674 AA F 49 Lar Ht Current MD ERCC4 c.109C>T p.R37C -- Damaging c.109C>T p.R37C -- Damaging 
¥ Ethnicity (C = Caucasian; AA = African American; H = Hispanic); * OP = oropharynx; Lar = larynx; OC = oral cavity; † L = leukopenia; A = anemia; Ht = short stature; ¥ MD = Missing Data 
‡ SLX4 deletion removes the entire gene (deletion coordinates: chr16_3586230-3740926) 
β carries a third mutation in BRCA2, also predicted to be benign (c.125A>G; p.Y42C) 
§ FANCB is X-linked 
** Previously reported in the Leiden Open Variation Database for Fanconi anemia (http://www.rockefeller.edu/fanconi/) and/or ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) 
†† Functional prediction consensus result from SIFT, PolyPhen, MutationTaster, CADD, and GERP++; synonymous variants analyzed by SILVA and NetGene2; nonsense mutations, 
indels, and the large deletion presumed to be damaging by nature of variant. 
^ synonymous variant predicted to effect splicing 

















Table 3. Variant counts, for each FA gene, and number of occurrences present in our HNSCC cohort, 
characterized as Rare, Predicted damaging, and Predicted damaging & reported 
 
Rare – exists at a frequency <.5% in 1000Genomes, NHLBI-ESP6500, or ExAC 
Predicted damaging – prediction algorithim (criteria); SIFT (D), Polyphen (D or P), MutationTaster (D or 
A), CADD (Phred-scaled score > 20), GERP++ (RS score > 2). If 4/5 of the required criteria were met, the 
variant was considered to be “predicted damaging”. 
Predicted damaging & reported – The above criteria were met and the variant was present in either the 






Predicted damaging & 
reported 
(57 patients) 
Gene variants # occurrences variants # occurrences variants # occurrences 
FANCA 20 22 7 9 2 2 
FANCB 1 1 0 0 0 0 
FANCC 6 8 4 5 3 4 
FANCD1/BRCA2 37 54 15 25 15 25 
FANCD2 11 11 6 6 2 2 
FANCE 6 6 5 5 1 1 
FANCF 2 2 2 2 0 0 
FANCG 6 6 1 1 0 0 
FANCI 17 20 11 14 2 2 
FANCJ/BRIP1 8 13 4 5 3 4 
FANCL 8 13 3 8 0 0 
FANCM 20 27 12 13 0 0 
FANCN/PALB2 12 15 3 3 2 2 
FANCO/RAD51C 3 4 2 3 2 3 
FANCP/SLX4 25 36 9 14 3 8 
FANCQ/ERCC4 12 17 7 12 3 7 
 194 255 91 125 38 60 
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Table 4. Distribution of rare FA gene variants among HNSCC patients, segregated by cancer site, age of onset, and ethnicity 
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Ethnicity 4 12 22 4 3 16 5 2 29 0 
 
1 4 4 5 38 0 2 7 71 0  1 2 6 3 5 9 0  255 
Age Group 38 23 36 9 43 80 3 6 17  



















Table 5. Analysis of FA gene mutation burden in HNSCC patients 
FA Gene Adjusted p-value HNSCC direction 
FANCA 0.93744 -- 
FANCB 2.8672 -- 
FANCC 15.3552 -- 
FANCD1 [BRCA2] 3.52E-15  
FANCD2 3.52E-15  
FANCE 0.0081088  
FANCF 1.55936 -- 
FANCG 3.52E-15  
FANCI 11.1664 -- 
FANCJ [BRIP1] 2.5776 -- 
FANCL 3.52E-15  
FANCM 8.1728 -- 
FANCN [PALB2] 6.2352 -- 
FANCO [RAD51C] 14.776 -- 
FANCP [SLX4] 1.7248 -- 
FANCQ [ERCC4 or XPF] 3.52E-15  
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Figure 1. Schematics of FA gene variant analysis in HNSCC patients.  
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Figure 2. ^nonsense group includes stoploss; *splicing group includes a synonymous variant  
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Supplemental Table 1. Comparison between samples included in the study and samples excluded 
 Cases selected (n=417) Cases unselected (n=230)  
Variables n (%) n (%) p-value 
Age, mean (SD) 43.1 (6.1) 42.5 (6.6) 0.514 
Age, grouped     0.566 
  <45 195 (46.8) 113 (49.1)  
  45-49 222 (53.2) 117 (50.9)  
Sex     1.0 
  Male 306 (73.4) 169 (73.5)  
  Female 111 (26.6) 61 (26.5)  
Race     1.0 
  Non-Hispanic whites 356 (85.4) 197 (85.7)  
  Others 61 (14.6) 33 (14.3)  
Site     <0.001 
  Oral cavity 149 (35.7) 61 (26.5)  
  Oropharynx* 230 (55.2) 127 (55.2)  
  Larynx/hypopharynx^ 38 (9.1) 39 (17.0)  
  SYN 0 (0) 3 (1.3)  
Smoking     0.067 
  Current 136 (34.5) 83 (38.8)  
  Former 68 (17.3) 48 (22.4)  
  Never 190 (48.2) 83 (38.8)  
Alcohol drinking     0.284 
  Current 194 (49.1) 112 (52.3)  
  Former 57 (14.4) 37 (17.3)  
  Never 144 (36.5) 65 (30.4)  
*The oropharynx group includes five patients with upper neck lymph node metastasis with unidentified primary site 
^The larynx group includes three patients with hypopharyngeal cancer 
"SYN" = patients with synchronous primaries at more than one site 
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Supplemental Table 2: High quality sequence coverage of FA gene regions for HNSCC samples 
Name RefSeq Gene ID UCSC Transcript ID chr start end
TargetSize 
(bp)
FANCA NM_000135 uc002fou.1 chr16 89803958 89888065 84107
FANCB NM_001018113 uc004cwg.1 chrX 14861528 14896184 34656
FANCC NM_000136 uc004avh.3 chr9 97861335 98084991 223656
FANCD1/BRCA2 NM_000059 uc001uub.1 chr13 32884616 32973809 89193
FANCD2 NM_001018115 uc003bux.1 chr3 10063112 10143614 80502
FANCE NM_021922 uc003oko.1 chr6 35415137 35434881 19744
FANCF NM_022725 uc001mql.1 chr11 22644078 22652387 8309
FANCG NM_004629 uc003zwb.1 chr9 35073834 35085013 11179
FANCI NM_001113378 uc010bnp.1 chr15 89782193 89860362 78169
FANCJ/BRIP1 NM_032043 uc002izk.2 chr17 59756546 59945920 189374
FANCL NM_018062.3 uc002rzw.4 chr2 58386377 58473515 87138
FANCM NM_020937.2 uc001wwd.4 chr14 45600135 45670093 69958
FANCN/PALB2 NM_024675.3 uc002dlx.1 chr16 23614482 23657678 43196
FANCO/RAD51C NM_058216.1 uc002iwu.3 chr17 56764962 56811692 46730
FANCP/SLX4 NM_032444.2 uc002cvp.2 chr16 3631183 3666585 35402
FANCQ/ERCC4 NM_005236 uc002dce.2 chr16 14009014 14046205 37191
Coverage refers to high quality sequence score for the targeted region,   MPG score >=10.
• Coverage of  CDS for the FANCA, FANCB and FANCB of 98%, 99% and 93% resepctively is exclusively to the reduced coverage of exon 1 in these genes
Coverage (entire gene)
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Coverage % CDS (bp)
Minimum 
(bp) Maximum (bp)
96.22 92.86 97.83 4373 4294 4294
95.67 93.67 97.56 2580 2418 2580
94.33 93.00 95.19 1827 1827 1827
94.35 93.21 95.24 10257 10257 10257
93.03 90.59 94.71 4491 4483 4490
98.50 95.91 99.50 1611 1362 1516
95.89 93.73 99.76 1125 1124 1125
98.31 93.83 99.99 1869 1868 1869
96.76 95.03 97.86 3987 3987 3987
96.35 95.13 97.47 3750 3750 3750
90.13 89.03 90.87 1143 1142 1143
98.66 97.20 99.79 6155 6154 6155
93.37 90.28 95.62 3561 3561 3561
93.64 90.85 96.37 1135 1134 1135
94.92 92.71 96.19 5686 5569 5686
99.27 97.56 100.00 2570 2517 2570
• Coverage of  CDS for the FANCA, FANCB and FANCB of 98%, 99% and 93% resepctively is exclusively to the reduced coverage of exon 1 in these genes
Coverage (entire gene) Coverage (coding region)




























































































































































185/417 HNSCC patients carry 194 rare FA gene variants
Including 1 large deletion from SNP array & 1 synonymous variant
80 variants are predicted to be damaging by prediction algorithms (at least 4 out of 5 agree - SIFT, Polyphen, MutationTaster, CADD, GERP++)
11 variants are pr dicted to be damaging due to the nature of the variant
65 variants are predicted to be benign by prediction algorithms (at least 4 out of 5 agree - SIFT, Polyphen, MutationTaster, CADD, GERP++)
39 variants have inconsistent predictions (at least 4 out of 5 do not agree - SIFT, Polyphen, MutationTaster, CADD, GERP++)
56 variants are present in the FA Mutation database (FAMutdb)
19 of these are predicted to be benign
27 are predicted to be damaging
10 have inconsistent predictions
SIFT Damaging if "D"
Polyphen Damaging if "P" or "D"
MutationTaster Damaging if "A" or "D"
CADD Damaging if >= 20 (top 1% most damaging variants in the genome)
GERP++ Conserved position if > 2 (RS score threshold of 2 provides high sensitivity while still strongly enriching for truly constrained sites)
nature of variant Damaging if variant is of the type: stopgain, indel, large deletion, synonymous predicted to induce splicing, 
"reported in FAmutDB/ClinVar/BIC" -- variant is present in at least one of these databases
"unreproted rare variant" -- variant is not present in FAmutDB, ClinVar, or BIC, but is observed in the 1000 Genomes, NHLBI-ESP, and/or ExAC
"novel" -- variant has not been reported to FAmutDB, ClinVar, or BIC, nor is it observed in the 1000 Genomes, NHLBI-ESP, or ExAC
chr start end Column1 ref alt gene
2 58386933 58386933 2:58386933-58386933 - AATT FANCL
2 58387285 58387286 2:58387285-58387286 CT - FANCL
2 58388673 58388673 2:58388673-58388673 - ATTT FANCL
2 58456974 58456974 2:58456974-58456974 C T FANCL
3 10085255 10085255 3:10085255-10085255 - TGGA FANCD2
3 10106085 10106085 3:10106085-10106085 G T FANCD2
3 10122823 10122823 3:10122823-10122823 C T FANCD2
6 35424011 35424013 6:35424011-35424013 GGA - FANCE
6 35427507 35427507 6:35427507-35427507 T C FANCE
9 35074140 35074140 9:35074140-35074140 A G FANCG
9 35075959 35075959 9:35075959-35075959 C G FANCG
9 97873915 97873915 9:97873915-97873915 A G FANCC
9 98011571 98011571 9:98011571-98011571 C T FANCC
13 32911967 32911967 13:32911967-32911967 T A BRCA2
14 45605328 45605328 14:45605328-45605328 C T FANCM
Supplemental Table 3: Characteristics of rare variants from sequence analysis of 16 FA genes in 417 HNSCC patients
Variant Info
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4 45669125 45669127 14:45669125-45669127 GAG - FANCM
5 89835919 89835919 15:89835919-89835919 G T FANCI
5 89838241 89838241 15:89838241-89838241 A G FANCI
5 89859688 89859688 15:89859688-89859688 T A FANCI
6 3586230 3740926 16:3586230-3740926 -- -- SLX4
6 3639105 3639105 16:3639105-3639105 C T SLX4
6 3639265 3639265 16:3639265-3639265 C A SLX4
6 3639375 3639375 16:3639375-3639375 G C SLX4
6 3639723 3639723 16:3639723-3639723 G A SLX4
6 3639900 3639900 16:3639900-3639900 C T SLX4
6 3641275 3641275 16:3641275-3641275 C G SLX4
6 3641304 3641304 16:3641304-3641304 C G SLX4
6 14028111 14028111 16:14028111-14028111 A C ERCC4
6 14028150 14028150 16:14028150-14028150 G C ERCC4
6 14029125 14029125 16:14029125-14029125 G T ERCC4
6 14029136 14029136 16:14029136-14029136 C A ERCC4
6 23641406 23641406 16:23641406-23641406 T C PALB2
6 23646577 23646578 16:23646577-23646578 CT - PALB2
6 89807245 89807245 16:89807245-89807245 C A FANCA
6 89831326 89831326 16:89831326-89831326 C T FANCA
6 89849271 89849271 16:89849271-89849271 G T FANCA
6 89857890 89857890 16:89857890-89857890 A G FANCA
7 59878645 59878645 17:59878645-59878645 T C BRIP1
10115047 10115047 3:10115047-10115047 G A FANCD2
35426215 35426215 6:35426215-35426215 C T FANCE
5 89824480 89824480 15:89824480-89824480 T A FANCI
5 89849381 89849381 15:89849381-89849381 G - FANCI
6 3639378 3639378 16:3639378-3639378 T A SLX4
6 3640271 3640271 16:3640271-3640271 G T SLX4
6 3640461 3640461 16:3640461-3640461 G A SLX4
6 3641280 3641280 16:3641280-3641280 C T SLX4
6 3647691 3647691 16:3647691-3647691 T C SLX4
6 3656645 3656645 16:3656645-3656645 A G SLX4
58386913 58386913 2:58386913-58386913 C G FANCL
58392901 58392901 2:58392901-58392901 C G FANCL
58456962 58456962 2:58456962-58456962 C G FANCL
10070369 10070369 3:10070369-10070369 T C FANCD2
10107551 10107551 3:10107551-10107551 G C FANCD2
10107587 10107587 3:10107587-10107587 A G FANCD2
10132062 10132062 3:10132062-10132062 C T FANCD2
35423672 35423672 6:35423672-35423672 C T FANCE
35427531 35427531 6:35427531-35427531 T C FANCE
35075077 35075077 9:35075077-35075077 C T FANCG
35077006 35077006 9:35077006-35077006 G T FANCG
1 22646497 22646497 11:22646497-22646497 T C FANCF
1 22646921 22646921 11:22646921-22646921 G C FANCF
4 45605397 45605397 14:45605397-45605397 G A FANCM
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4 45605405 45605405 14:45605405-45605405 G C FANCM
4 45605503 45605503 14:45605503-45605503 C T FANCM
4 45605551 45605551 14:45605551-45605551 A G FANCM
4 45605730 45605730 14:45605730-45605730 G A FANCM
4 45606286 45606286 14:45606286-45606286 T C FANCM
4 45618149 45618149 14:45618149-45618149 T C FANCM
4 45623204 45623204 14:45623204-45623204 G C FANCM
4 45628478 45628478 14:45628478-45628478 C G FANCM
4 45633740 45633740 14:45633740-45633740 T C FANCM
4 45644816 45644816 14:45644816-45644816 A C FANCM
4 45645661 45645661 14:45645661-45645661 G T FANCM
4 45645784 45645784 14:45645784-45645784 C T FANCM
4 45645892 45645892 14:45645892-45645892 T C FANCM
4 45658326 45658326 14:45658326-45658326 C T FANCM
4 45658342 45658342 14:45658342-45658342 A C FANCM
4 45665612 45665612 14:45665612-45665612 C T FANCM
4 45669105 45669105 14:45669105-45669105 T C FANCM
5 89804889 89804889 15:89804889-89804889 T C FANCI
5 89811698 89811698 15:89811698-89811698 T C FANCI
5 89811742 89811742 15:89811742-89811742 G A FANCI
5 89819943 89819943 15:89819943-89819943 G A FANCI
5 89824418 89824418 15:89824418-89824418 G A FANCI
5 89825056 89825056 15:89825056-89825056 A G FANCI
5 89826381 89826381 15:89826381-89826381 G A FANCI
5 89843162 89843162 15:89843162-89843162 A G FANCI
5 89848573 89848573 15:89848573-89848573 A T FANCI
5 89849316 89849316 15:89849316-89849316 C T FANCI
5 89859649 89859649 15:89859649-89859649 G A FANCI
6 3633211 3633211 16:3633211-3633211 C A SLX4
6 3639991 3639991 16:3639991-3639991 C A SLX4
6 3642722 3642722 16:3642722-3642722 C G SLX4
6 3642737 3642737 16:3642737-3642737 G C SLX4
6 3642845 3642845 16:3642845-3642845 C T SLX4
6 3644515 3644515 16:3644515-3644515 C T SLX4
6 3647490 3647490 16:3647490-3647490 G A SLX4
6 3651147 3651147 16:3651147-3651147 C A SLX4
6 3652236 3652236 16:3652236-3652236 C T SLX4
6 3656698 3656698 16:3656698-3656698 C A SLX4
6 14014131 14014131 16:14014131-14014131 C T ERCC4
6 14029437 14029437 16:14029437-14029437 C T ERCC4
6 14041578 14041578 16:14041578-14041578 G A ERCC4
6 14042100 14042100 16:14042100-14042100 G A ERCC4
6 23637718 23637718 16:23637718-23637718 T C PALB2
6 89811442 89811442 16:89811442-89811442 C G FANCA
6 89816220 89816220 16:89816220-89816220 G A FANCA
6 89818612 89818612 16:89818612-89818612 G C FANCA
6 89836359 89836359 16:89836359-89836359 G A FANCA
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16 89842161 89842161 16:89842161-89842161 T A FANCA
16 89842176 89842176 16:89842176-89842176 C G FANCA
16 89858916 89858916 16:89858916-89858916 G A FANCA
16 89865628 89865628 16:89865628-89865628 G A FANCA
16 89871709 89871709 16:89871709-89871709 C T FANCA
16 89877149 89877149 16:89877149-89877149 C T FANCA
16 89877377 89877377 16:89877377-89877377 G A FANCA
16 89877386 89877386 16:89877386-89877386 G C FANCA
17 56780607 56780607 17:56780607-56780607 A G RAD51C
X 14883603 14883603 X:14883603-14883603 G T FANCB
2 58390589 58390589 2:58390589-58390589 A C FANCL
9 98011497 98011497 9:98011497-98011497 G A FANCC
13 32953550 32953550 13:32953550-32953550 G A BRCA2
13 32914815 32914815 13:32914815-32914815 G A BRCA2
13 32893369 32893369 13:32893369-32893369 G C BRCA2
17 59885856 59885856 17:59885856-59885856 T C BRIP1
13 32953549 32953549 13:32953549-32953549 G T BRCA2
13 32968861 32968861 13:32968861-32968861 T C BRCA2
16 23646942 23646942 16:23646942-23646942 T C PALB2
13 32911295 32911295 13:32911295-32911295 G A BRCA2
13 32907401 32907401 13:32907401-32907401 G C BRCA2
13 32900252 32900252 13:32900252-32900252 A G BRCA2
15 89835982 89835982 15:89835982-89835982 C A FANCI
16 3632567 3632567 16:3632567-3632567 G A SLX4
17 59924572 59924572 17:59924572-59924572 G A BRIP1
13 32907419 32907419 13:32907419-32907419 G A BRCA2
13 32953604 32953604 13:32953604-32953604 G A BRCA2
13 32906766 32906766 13:32906766-32906766 C T BRCA2
13 32937521 32937521 13:32937521-32937521 G A BRCA2
17 59924505 59924505 17:59924505-59924505 A G BRIP1
13 32914809 32914809 13:32914809-32914809 T C BRCA2
13 32972771 32972771 13:32972771-32972771 C T BRCA2
13 32929047 32929047 13:32929047-32929047 G C BRCA2
9 98009786 98009786 9:98009786-98009786 C T FANCC
3 10074646 10074646 3:10074646-10074646 G C FANCD2
3 10103845 10103845 3:10103845-10103845 C T FANCD2
3 10122797 10122797 3:10122797-10122797 G A FANCD2
6 35426122 35426122 6:35426122-35426122 G C FANCE
9 35075738 35075738 9:35075738-35075738 G T FANCG
9 35079445 35079445 9:35079445-35079445 T C FANCG
16 14014038 14014038 16:14014038-14014038 C T ERCC4
16 14029516 14029516 16:14029516-14029516 G C ERCC4
16 14041570 14041570 16:14041570-14041570 T C ERCC4
16 89805672 89805672 16:89805672-89805672 C T FANCA
16 89836978 89836978 16:89836978-89836978 G A FANCA
16 89877157 89877157 16:89877157-89877157 C T FANCA
13 32918724 32918724 13:32918724-32918724 A G BRCA2
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3 32953616 32953616 13:32953616-32953616 C T BRCA2
7 59821830 59821830 17:59821830-59821830 C A BRIP1
3 32893386 32893386 13:32893386-32893386 A G BRCA2
3 32914328 32914328 13:32914328-32914328 T C BRCA2
3 32906571 32906571 13:32906571-32906571 A C BRCA2
3 32930598 32930598 13:32930598-32930598 T C BRCA2
3 32945172 32945172 13:32945172-32945172 A C BRCA2
3 32911754 32911754 13:32911754-32911754 C T BRCA2
3 32929042 32929042 13:32929042-32929042 C G BRCA2
6 23637715 23637715 16:23637715-23637715 G A PALB2
3 32906502 32906502 13:32906502-32906502 A G BRCA2
6 23619286 23619286 16:23619286-23619286 C G PALB2
6 23647211 23647211 16:23647211-23647211 T C PALB2
6 23652456 23652456 16:23652456-23652456 G A PALB2
3 32905152 32905153 13:32905152-32905153 GA - BRCA2
6 89813298 89813298 16:89813298-89813298 T C FANCA
97864005 97864005 9:97864005-97864005 A G FANCC
3 32912735 32912735 13:32912735-32912735 G T BRCA2
6 14041848 14041848 16:14041848-14041848 C T ERCC4
98009773 98009773 9:98009773-98009773 A C FANCC
6 23619288 23619288 16:23619288-23619288 C T PALB2
3 32911175 32911175 13:32911175-32911175 G A BRCA2
7 59926512 59926512 17:59926512-59926512 C T BRIP1
3 32911700 32911700 13:32911700-32911700 G T BRCA2
3 32907407 32907407 13:32907407-32907407 A G BRCA2
3 32893271 32893271 13:32893271-32893271 A G BRCA2
7 56787304 56787304 17:56787304-56787304 G A RAD51C
3 32913271 32913271 13:32913271-32913271 A C BRCA2
7 59870998 59870998 17:59870998-59870998 T C BRIP1
3 32911818 32911818 13:32911818-32911818 C T BRCA2
6 23641186 23641186 16:23641186-23641186 C G PALB2
6 23646872 23646872 16:23646872-23646872 A T PALB2
6 23649272 23649272 16:23649272-23649272 C T PALB2
7 56774172 56774172 17:56774172-56774172 G A RAD51C
7 59761303 59761303 17:59761303-59761303 C T BRIP1
3 32954018 32954018 13:32954018-32954018 G A BRCA2
3 32945178 32945178 13:32945178-32945178 A G BRCA2
3 32937324 32937324 13:32937324-32937324 C A BRCA2
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le80 variants are predicted to be damaging by prediction algorithms (at least 4 out of 5 agree - SIFT, Polyphen, MutationTaster, CADD, GERP++)
65 variants are predicted to be benign by prediction algorithms (at least 4 out of 5 agree - SIFT, Polyphen, MutationTaster, CADD, GERP++)
39 variants have inconsistent predictions (at least 4 out of 5 do not agree - SIFT, Polyphen, MutationTaster, CADD, GERP++)
Conserved position if > 2 (RS score threshold of 2 provides high sensitivity while still strongly enriching for truly constrained sites)
Damaging if variant is of the type: stopgain, indel, large deletion, synonymous predicted to induce splicing, 
"unreproted rare variant" -- variant is not present in FAmutDB, ClinVar, or BIC, but is observed in the 1000 Genomes, NHLBI-ESP, and/or ExAC
"novel" -- variant has not been reported to FAmutDB, ClinVar, or BIC, nor is it observed in the 1000 Genomes, NHLBI-ESP, or ExAC
type # occurrences note protein cDNA (hgvs) SIFT
frameshift insertion 6 p.P370fs c.1094_1095insAATTfs
frameshift deletion 1 p.Q355fs c.1049_1050delfs
frameshift insertion 1 p.Q340fs c.1003_1004insAAATfs
nonsynonymous SNV 1 p.S64N c.191G>A T
frameshift insertion 1 p.T359fs c.1077_1078insTGGAfs
nonsynonymous_SNV 1 p.V665L c.1993G>T T
stopgain 1 p.Q1006X c.3016C>T .
nonframeshift deletion 1 p.246_246del c.736_738delnfs
nonsynonymous SNV 1 p.L429P c.1286T>C D
nonsynonymous SNV 1 p.F612L c.1834T>C T
nonsynonymous SNV 1 p.R381S c.1143G>C T
nonsynonymous SNV 1 p.C387R c.1159T>C T
nonsynonymous SNV 1 p.M1I c.3G>A D
nonsynonymous SNV 1 p.C1159S c.3475T>A T
nonsynonymous SNV 1 p.P32S c.94C>T D
Supplemental Table 3: Characteristics of rare variants from sequence analysis of 16 FA genes in 417 HNSCC patients







































































nonframeshift deletion 1 p.2021_2021delc.6061_6063delnfs
nonsynonymous SNV 1 p.D665Y c.1993G>T D
nonsynonymous SNV 1 p.Q851R c.2552A>G T
stoploss 1 p.X1329K c.3985T>A .
large deletion 1 deletion spans entire gene-- -- ld
nonsynonymous SNV 1 p.D1512N c.4534G>A D
nonsynonymous SNV 1 p.M1458I c.4374G>T T
nonsynonymous SNV 1 p.P1422A c.4264C>G T
stopgain 1 p.Q1306X c.3916C>T .
nonsynonymous SNV 1 p.E1247K c.3739G>A D
nonsynonymous SNV 1 p.Q788H c.2364G>C T
nonsynonymous SNV 1 p.V779L c.2335G>C T
nonsynonymous SNV 1 p.K389Q c.1165A>C T
nonsynonymous SNV 1 p.G402R c.1204G>C T
nonsynonymous SNV 1 p.A446S c.1336G>T T
synonymous 1 predicted to affect splicingp.V449V c.1347C>A syn
nonsynonymous SNV 1 p.Q690R c.2069A>G T
frameshift deletion 1 p.Q430fs c.1289_1290delfs
nonsynonymous SNV 1 p.L1265F c.3795G>T D
nonsynonymous SNV 1 p.R917Q c.2750G>A T
nonsynonymous SNV 1 p.T541N c.1622C>A T
nonsynonymous SNV 1 p.M427T c.1280T>C D
nonsynonymous SNV 1 p.N370S c.1109A>G T
splicing 1 -- c.2715+1G>A.
nonsynonymous SNV 1 p.R371W c.1111C>T D
stopgain 1 p.Y487X c.1461T>A .
frameshift deletion 1 p.D1105fs c.3493delG fs
nonsynonymous SNV 3 p.I1421F c.4261A>T D
nonsynonymous SNV 4 p.S1123Y c.3368C>A D
nonsynonymous SNV 2 p.R1060W c.3178C>T D
nonsynonymous SNV 2 p.E787K c.2359G>A T
nonsynonymous SNV 2 p.K458E c.1372A>G D
nonsynonymous SNV 2 p.V197A c.590T>C T
nonsynonymous SNV 1 p.G377A c.1115G>C T
nonsynonymous SNV 1 p.E222Q c.649G>C T
nonsynonymous SNV 1 p.R68P c.203G>C T
nonsynonymous SNV 1 p.S10P c.28T>C T
nonsynonymous SNV 1 p.C758S c.2273G>C D
nonsynonymous SNV 1 p.K770R c.2309A>G T
nonsynonymous SNV 1 p.S1257L c.3770C>T T
nonsynonymous SNV 1 p.L133F c.397C>T D
nonsynonymous SNV 1 p.M437T c.1310T>C D
nonsynonymous SNV 1 p.A495T c.1483G>A T
nonsynonymous SNV 1 p.Q247K c.739C>A T
nonsynonymous SNV 1 p.Y287C c.860A>G D
nonsynonymous SNV 1 p.L146V c.436C>G D
nonsynonymous SNV 1 p.D55N c.163G>A D
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nonsynonymous SNV 5 p.L57F c.171G>C T
nonsynonymous SNV 1 p.P90L c.269C>T D
nonsynonymous SNV 1 p.N106S c.317A>G D
nonsynonymous SNV 1 p.A166T c.496G>A T
nonsynonymous SNV 1 p.S175P c.523T>C T
nonsynonymous SNV 1 p.I290T c.869T>C D
nonsynonymous SNV 1 p.G378R c.1132G>C D
nonsynonymous SNV 2 p.L526V c.1576C>G D
nonsynonymous SNV 2 p.I587T c.1760T>C D
nonsynonymous SNV 1 p.K953N c.2859A>C D
nonsynonymous SNV 1 p.G1235V c.3704G>T D
nonsynonymous SNV 1 p.S1276L c.3827C>T T
nonsynonymous SNV 1 p.L1312P c.3935T>C D
stopgain 2 p.Q1701X c.5101C>T .
nonsynonymous SNV 1 p.N1706T c.5117A>C T
nonsynonymous SNV 1 p.R1860C c.5578C>T D
nonsynonymous SNV 1 p.V2014A c.6041T>C D
nonsynonymous SNV 1 p.L121P c.362T>C D
nonsynonymous SNV 2 p.I275T c.824T>C D
nonsynonymous_SNV 1 p.V290M c.868G>A T
nonsynonymous_SNV 1 p.V372I c.1114G>A T
nonsynonymous SNV 1 p.V467I c.1399G>A T
nonsynonymous SNV 3 p.M525V c.1573A>G D
nonsynonymous SNV 1 p.R533Q c.1598G>A D
nonsynonymous SNV 1 p.Y923C c.2768A>G D
nonsynonymous SNV 1 p.D1063V c.3188A>T D
nonsynonymous SNV 1 p.T1143I c.3428C>T T
nonsynonymous SNV 1 p.G1316R c.3946G>A T
nonsynonymous SNV 1 p.R1680S c.5040G>T T
nonsynonymous SNV 1 p.Q1216H c.3648G>T T
nonsynonymous SNV 2 p.E769Q c.2305G>C T
nonsynonymous SNV 1 p.P764A c.2290C>G T
nonsynonymous SNV 1 p.A728T c.2182G>A D
nonsynonymous SNV 1 p.G700E c.2099G>A D
nonsynonymous SNV 1 p.R525C c.1573C>T T
nonsynonymous SNV 1 p.Q332H c.996G>T D
nonsynonymous SNV 1 p.R278Q c.833G>A T
nonsynonymous SNV 1 p.E179D c.537G>T D
nonsynonymous SNV 2 homozygous p.R37C c.109C>T D
nonsynonymous SNV 1 p.P550S c.1648C>T T
nonsynonymous SNV 1 p.V709M c.2125G>A D
nonsynonymous SNV 1 p.E883K c.2647G>A T
nonsynonymous SNV 1 p.N863D c.2587A>G T
nonsynonymous SNV 1 p.R1184P c.3551G>C D
nonsynonymous SNV 1 p.R1053C c.3157C>T T
nonsynonymous SNV 1 p.H1000Q c.3000C>G T
nonsynonymous SNV 1 p.A797V c.2390C>T T
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nonsynonymous SNV 1 p.E630V c.1889A>T D
nonsynonymous SNV 3 p.C625S c.1874G>C D
nonsynonymous SNV 1 p.A349V c.1046C>T T
nonsynonymous SNV 1 p.A280V c.839C>T D
nonsynonymous SNV 1 p.V230I c.688G>A T
nonsynonymous SNV 1 p.R163H c.488G>A D
nonsynonymous SNV 1 p.A129V c.386C>T T
nonsynonymous SNV 1 p.T126R c.377C>G T
nonsynonymous SNV 1 p.I208V c.622A>G T
nonsynonymous SNV 1 p.N10K c.30C>A T
nonsynonymous SNV 1 p.F257C c.755T>G T
nonsynonymous SNV 1 p.S26F c.77C>T D
nonsynonymous_SNV 6 p.A2951T c.8851G>A D
nonsynonymous SNV 1 p.R2108H c.6323G>A T
nonsynonymous SNV 2 p.A75P c.223G>C D
nonsynonymous SNV 5 p.K297R c.890A>G T
nonsynonymous SNV 1 p.K2950N c.8850G>T D
nonsynonymous SNV 1 p.Y3098H c.9292T>C T
nonsynonymous_SNV 1 p.I309V c.925A>G T
nonsynonymous SNV 1 p.D935N c.2803G>A D
nonsynonymous SNV 2 p.D596H c.1786G>C D
nonsynonymous SNV 1 p.Q147R c.440A>G T
nonsynonymous_SNV 1 p.Q686K c.2056C>A T
nonsynonymous_SNV 2 p.R1761C c.5281C>T T
nonsynonymous SNV 2 p.R173C c.517C>T D
nonsynonymous SNV 1 p.G602R c.1804G>A T
nonsynonymous SNV 1 p.V2969M c.8905G>A D
nonsynonymous SNV 1 p.S384F c.1151C>T D
nonsynonymous SNV 2 p.V2728I c.8182G>A T
nonsynonymous SNV 1 p.L195P c.584T>C T
nonsynonymous SNV 1 p.L2106P c.6317T>C T
nonsynonymous SNV 1 p.T3374I c.10121C>T D
nonsynonymous SNV 2 p.G2353R c.7057G>C D
nonsynonymous SNV 2 p.V60I c.178G>A T
nonsynonymous_SNV 1 p.Q65H c.195G>C D
nonsynonymous SNV 1 p.P593S c.1777C>T T
nonsynonymous SNV 1 p.R997Q c.2990G>A T
nonsynonymous SNV 1 p.G340R c.1018G>C T
nonsynonymous SNV 1 p.P386H c.1157C>A T
nonsynonymous SNV 1 p.Q26R c.77A>G T
nonsynonymous SNV 1 p.P6S c.16C>T T
nonsynonymous SNV 1 p.R576T c.1727G>C T
nonsynonymous SNV 4 p.I706T c.2117T>C D
nonsynonymous SNV 1 p.A1346T c.4036G>A T
nonsynonymous SNV 1 p.P739L c.2216C>T D
nonsynonymous SNV 1 p.M160I c.480G>A T
nonsynonymous SNV 1 p.N2291D c.6871A>G T
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nonsynonymous SNV 2 p.R2973C c.8917C>T D
nonsynonymous SNV 1 p.Q740H c.2220G>T D
nonsynonymous SNV 1 p.I80M c.240A>G T
nonsynonymous SNV 1 p.S1946P c.5836T>C T
nonsynonymous SNV 1 p.N319T c.956A>C D
nonsynonymous_SNV 4 p.I2490T c.7469T>C T
nonsynonymous SNV 1 p.E2856A c.8567A>C T
nonsynonymous SNV 1 p.P1088S c.3262C>T T
nonsynonymous SNV 1 p.A2351G c.7052C>G D
nonsynonymous SNV 4 p.P864S c.2590C>T T
nonsynonymous SNV 1 p.Y296C c.887A>G T
nonsynonymous SNV 1 p.E1083D c.3249G>C D
nonsynonymous SNV 1 p.D219G c.656A>G T
nonsynonymous SNV 1 p.P8L c.23C>T D
frameshift deletion 1 p.E260fs c.778_779delfs
nonsynonymous SNV 1 p.R1117G c.3349A>G D
nonsynonymous SNV 2 p.L554P c.1661T>C D
stopgain 1 p.E1415X c.4243G>T .
nonsynonymous SNV 2 p.R799W c.2395C>T D
nonsynonymous SNV 1 p.F64C c.191T>G D
nonsynonymous SNV 1 p.E1083K c.3247G>A D
nonsynonymous SNV 1 p.A895T c.2683G>A T
nonsynonymous SNV 1 p.R162Q c.485G>A D
nonsynonymous SNV 1 p.A1070S c.3208G>T T
nonsynonymous SNV 3 p.T598A c.1792A>G T
nonsynonymous_SNV 2 p.Y42C c.125A>G T
nonsynonymous SNV 2 p.G264S c.790G>A D
nonsynonymous SNV 1 p.E1593D c.4779A>C T
nonsynonymous SNV 1 p.H478R c.1433A>G T
nonsynonymous SNV 2 p.A1109V c.3326C>T D
nonsynonymous SNV 1 p.L763F c.2289G>C D
nonsynonymous SNV 1 p.L332H c.995T>A D
nonsynonymous SNV 1 p.R37H c.110G>A D
nonsynonymous SNV 1 p.A175T c.523G>A D
nonsynonymous SNV 1 p.R1035H c.3104G>A D
nonsynonymous SNV 1 p.A3029T c.9085G>A D
nonsynonymous SNV 1 p.Q2858R c.8573A>G D
nonsynonymous SNV 1 p.T2662K c.7985C>A D
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B N 0.126 -4.57
fs fs fs
D D 24.5 5.58
. A 38 4.91
nfs nfs nfs
D D 25.7 5.41
B N 11.97 4.25
B D 19.27 5.33
B N 0.015 -2.75
D D 29.7 5.13
B N 0.001 -3.49
P N 23.5 2.76
Prediction Results
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D D 28.7 5.97
D D 20.7 4.71
. N 10.09 -4.08
ld ld ld
D D 28.3 5.67
B N 0.04 -11.3
P N 0.074 3.78
. A 35 2.43
D N 23.9 4.7
D N 12.73 -3.65
B N 19.52 -0.651
B D 9.398 5.91
B D 25.7 5.91
B D 19.08 5.78
syn syn syn
B N 0.002 -3.38
fs fs fs
D D 27 1.87
B N 5.401 0.027
P N 4.896 3.22
P D 21.6 5.43
D D 23.6 5.13
. D 25.4 5.83
D D 35 3.48
. A 38 4.83
fs fs fs
P N 13.21 -4.05
P N 25.4 6.07
B N 14.1 2.83
P N 22.7 1.33
D N 27.1 4.22
B N 0.024 -3.52
B D 7.847 3.35
B D 23.9 4.85
B D 22.4 2.99
D N 21.7 1.47
D D 27.8 5.68
B N 10.59 -2.5
B N 14.18 2.58
D N 25.7 5.37
P N 23.6 5.41
B N 8.56 1.25
P D 23.8 5.12
D D 28.3 4.23
D D 25 5.2
D D 31 4.99
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B D 17.99 1.07
P D 27.9 5.65
D D 25.3 5.65
D D 29.2 5.52
B N 9.26 -1.38
B D 22.7 5.55
D D 29 4.88
B D 17.71 3.42
B N 23.1 5.94
D N 22.8 1.19
D D 27.6 5.61
B N 1.058 2.24
B N 3.258 -7.41
. A 35 -2.53
B N 0.003 -0.275
D D 35 5.27
D D 26.8 5.93
D D 23.2 5.27
P D 23.1 3.54
B N 9.427 -0.231
P N 13.8 3.97
B D 10.24 -0.076
P D 23.1 4.67
D D 35 6.03
B N 15.55 -0.064
D D 27.2 5.92
D D 23.4 5.76
B N 5.046 0.541
B N 17.66 -0.564
B N 1.206 -2.5
B N 18.62 4.64
B N 0.003 -1.6
D N 25.9 4.65
D D 27 4.35
B N 15.35 -1.55
B N 21.8 1.16
B N 0.095 -5.38
B N 9.08 0.712
D D 35 5.13
D D 32 5.33
D D 32 5.49
B N 0.615 -10.5
B N 22.9 2.5
P N 15.18 -1.96
B N 3.673 -4.92
B N 1.19 3.01
B N 10.84 -9.26
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B N 19.26 3.93
D D 21.4 5.03
P N 23.2 3.48
D N 23.3 3.74
B N 0.626 -1.86
D D 26.2 4.01
B N 12.03 -3.76
B N 0.694 -10.1
P D 16.25 5.77
B N 0.002 -11.6
B D 13.07 1.24
D D 26.9 4.22
D D 29.5 5.6
B N 13.2 2.76
D D 23.8 5.59
P N 10.41 5.29
D D 24 1.76
B N 0.006 1.6
B N 0.001 -12.2
B N 8.869 -0.456
D N 24.9 3.38
B N 0.001 -1.65
B N 18.29 4.88
P D 21.1 2.21
D D 27.6 5.26
B N 18.77 3.64
P D 24.3 0.674
D N 23.4 3.52
B N 0.002 -7.77
B D 4.462 -0.011
B N 0.939 -5.6
B N 23.2 1.53
D N 27.9 2.97
B N 0.014 -5.4
D N 23.2 3.37
B N 0.004 2.2
B N 23.6 2.82
D N 23.1 3.6
B N 0.147 1.37
D D 16.64 4.96
B N 6.133 1.88
P D 24.1 5.33
D D 26.9 5.49
P N 6.518 -1.73
D D 25.6 4.9
P N 10.37 1.67
P N 23.5 2.43
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D D 33 4.61
D D 25.7 2.09
P N 23 1.6
B N 0.002 -9.18
P N 10.84 1.15
B N 8.41 -5.83
D D 28 5.28
B N 1.114 2.73
P N 23.1 2.03
P N 18.44 2.82
B N 0.005 -2.14
D N 23.1 3.8
B N 0.008 -5.08
B D 26.8 1.14
fs fs fs
D D 22.5 5.09
D A 25.7 4.76
. A 35 4.19
D A 35 6.16
D D 26.6 4.32
B N 23.7 3.05
B N 0.057 2.16
D D 34 5.85
B N 0.001 -2.47
B N 1.104 -2.76
B D 0.506 0.279
B D 24.9 6
B N 17.41 -1.14
D N 10.99 5.24
D D 31 5.75
D N 17.95 4
B N 13.49 3.3
D D 27.9 4.75
D D 28.7 4.67
B N 23.2 4.66
D D 28.4 4.81
D D 28.2 5.28
B N 25.3 4.93
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Prediction Consensus Database Presence FAMutdb ClinVar ClinVar_significance
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Indeterminate novel -- -- --
Benign novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Damaging novel -- -- --
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Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Indeterminate novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Benign novel -- -- --
Indeterminate novel -- -- --
Indeterminate novel -- -- --
Indeterminate novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Benign novel -- -- --
Indeterminate novel -- -- --
Damaging novel -- -- --
Damaging novel -- -- --
Damaging present in FAmutDB/ClinVar/BICYes -- --
Damaging present in FAmutDB/ClinVar/BICYes -- --
Damaging present in FAmutDB/ClinVar/BICYes -- --
Damaging present in FAmutDB/ClinVar/BICYes -- --
Indeterminate present in FAmutDB/ClinVar/BICYes -- --
Damaging present in FAmutDB/ClinVar/BICYes -- --
Indeterminate present in FAmutDB/ClinVar/BICYes -- --
Indeterminate present in FAmutDB/ClinVar/BICYes -- --
Damaging present in FAmutDB/ClinVar/BICYes -- --
Benign present in FAmutDB/ClinVar/BICYes -- --
Indeterminate unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
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Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
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Indeterminate unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Damaging unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Indeterminate unreported rare variants-- -- --
Benign unreported rare variants-- -- --
Benign present in FAmutDB/ClinVar/BIC-- Yes Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Benign|Benign|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Benign|Benign|Benign|Benign|Benign|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Benign|Benign|Benign|Uncertain significance|Benign|other,other|Uncertain significance
Damaging present in FAmutDB/ClinVar/BICYes Yes Benign|Benign|Uncertain significance|Benign|Uncertain significance|Benign
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes Benign|Likely benign|Likely benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Benign|Likely benign|Likely benign,Benign|other|Likely benign|Likely benign|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Benign|Likely benign|not provided|Benign|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Benign|not provided|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Benign|other|other|Benign|Benign,Uncertain significance|Uncertain significance|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Benign|other|other|Benign|Likely benign
Benign present in FAmutDB/ClinVar/BICYes Yes Benign|other|Uncertain significance|Benign|Benign,Uncertain significance|Uncertain significance
Benign present in FAmutDB/ClinVar/BIC-- Yes Likely benign
Damaging present in FAmutDB/ClinVar/BIC-- Yes Likely benign|Benign
Damaging present in FAmutDB/ClinVar/BIC-- Yes Likely benign|Benign|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Likely benign|Benign|Benign|Uncertain significance|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Likely benign|Benign|Benign|Uncertain significance|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Likely benign|Benign|Likely benign|Benign|not provided|Uncertain significance|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Likely benign|Benign|other|Benign|Likely benign|Benign|Benign,not provided|Benign
Benign present in FAmutDB/ClinVar/BIC-- Yes Likely benign|not provided|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Likely benign|other|Likely benign|Likely benign
Indeterminate present in FAmutDB/ClinVar/BICYes Yes Likely benign|other|not provided|Benign|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Likely benign|other|not provided|Uncertain significance|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes Likely benign|Uncertain significance
Damaging present in FAmutDB/ClinVar/BIC-- Yes not provided
Benign present in FAmutDB/ClinVar/BIC-- Yes not provided
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes not provided
Indeterminate present in FAmutDB/ClinVar/BICYes Yes not provided
Benign present in FAmutDB/ClinVar/BIC-- Yes not provided
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes not provided
Benign present in FAmutDB/ClinVar/BIC-- Yes not provided
Damaging present in FAmutDB/ClinVar/BIC-- Yes not provided
Damaging present in FAmutDB/ClinVar/BIC-- Yes not provided
Benign present in FAmutDB/ClinVar/BICYes Yes not provided
Damaging present in FAmutDB/ClinVar/BIC-- Yes not provided
Benign present in FAmutDB/ClinVar/BIC-- Yes not provided
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes not provided|Uncertain significance
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Damaging present in FAmutDB/ClinVar/BICYes Yes not provided|Uncertain significance,Benign|Uncertain significance|Likely benign|Benign
Damaging present in FAmutDB/ClinVar/BIC-- Yes not provided|Uncertain significance|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes not provided|Uncertain significance|Uncertain significance
Benign present in FAmutDB/ClinVar/BICYes Yes not provided|Uncertain significance|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BICYes Yes other|Benign|Benign|Benign,Likely benign|other|Benign|Uncertain significance
Benign present in FAmutDB/ClinVar/BICYes Yes other|Benign|other|Benign|Benign|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes other|Likely benign|Benign|Benign|Likely benign|Benign
Benign present in FAmutDB/ClinVar/BICYes Yes other|Likely benign|Likely benign|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes other|Likely benign|not provided|Likely benign|Benign,Uncertain significance|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BICYes Yes other|Likely benign|other|not provided
Benign present in FAmutDB/ClinVar/BICYes Yes other|not provided|Likely benign|other
Damaging present in FAmutDB/ClinVar/BICYes Yes other|Uncertain significance
Benign present in FAmutDB/ClinVar/BICYes Yes other|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BICYes Yes other|Uncertain significance
Damaging present in FAmutDB/ClinVar/BICYes Yes Pathogenic
Damaging present in FAmutDB/ClinVar/BICYes Yes Pathogenic
Damaging present in FAmutDB/ClinVar/BICYes Yes Pathogenic|not provided
Damaging present in FAmutDB/ClinVar/BIC-- Yes Pathogenic|not provided
Damaging present in FAmutDB/ClinVar/BICYes Yes Pathogenic|not provided
Damaging present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance
Benign present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance,Uncertain significance
Damaging present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance,Uncertain significance
Benign present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance,Uncertain significance|Uncertain significance
Benign present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Benign|Benign|Likely benign|Benign|Benign|Likely benign
Benign present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Benign|Likely benign|Benign|Benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Benign|Uncertain significance
Benign present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Likely benign|Uncertain significance|not provided|Benign
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance|not provided|Uncertain significance
Damaging present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance|other|Likely benign|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Uncertain significance
Damaging present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Uncertain significance
Damaging present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance|Uncertain significance
Damaging present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Uncertain significance|Benign|Likely benign
Damaging present in FAmutDB/ClinVar/BICYes Yes Uncertain significance|Uncertain significance|Likely benign|Uncertain significance
Indeterminate present in FAmutDB/ClinVar/BIC-- Yes Uncertain significance|Uncertain significance|Uncertain significance,Uncertain significance
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# Individuals 6503 2203 4300
ClinVar_DBN BIC BIC_significanceLOVD - IARC - BRCA2 (Tavtigian)esp6500_all esp6500_aa
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
NHLBI-ESP6500
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-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0.0002 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0.0006 0
-- -- -- 0.0008 0
-- -- -- 0.0007 0.0005
-- -- -- 0.0012 0.0009
-- -- -- 0.0002 0
-- -- -- 0.0021 0.0002
-- -- -- 0.0006 0.0018
-- -- -- 0.000077 0.0002
-- -- -- 0.0009 0.0005
-- -- -- 0.0002 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0 0
-- -- -- 0.0008 0.0002
-- -- -- 0.0002 0
-- -- -- 0.0014 0.0041
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0.0002 0
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-- -- -- 0.0018 0.0005
-- -- -- 0.0006 0.0005
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0.000077 0
-- -- -- 0.0009 0.0005
-- -- -- 0.0002 0.0002
-- -- -- 0.0017 0.0005
-- -- -- 0.000077 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0.0004 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0.000077 0
-- -- -- 0.000077 0
-- -- -- 0.0005 0.0002
-- -- -- 0.0172 0.0505
-- -- -- 0.0175 0.0516
-- -- -- 0.000077 0.0002
-- -- -- 0.0024 0.0007
-- -- -- 0.000077 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0 0
-- -- -- 0.0002 0
-- -- -- 0.0015 0.0005
-- -- -- 0.0021 0.0061
-- -- -- 0 0
-- -- -- 0.000077 0.0002
-- -- -- 0.000077 0.0002
-- -- -- 0.000077 0
-- -- -- 0.000077 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0.000077 0
-- -- -- 0.000077 0
-- -- -- 0.0002 0
-- -- -- 0 0
-- -- -- 0.000077 0
-- -- -- 0.0002 0
-- -- -- 0 0
-- -- -- 0.0003 0.0005
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-- -- -- 0 0
-- -- -- 0.0023 0.0007
-- -- -- 0.0002 0.0002
-- -- -- 0 0
-- -- -- 0.0002 0
-- -- -- 0.0002 0.0002
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
-- -- -- 0 0
Fanconi_anemia-- -- 0.000077 0.0002
not_specified|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia-- -- 0.005 0.0014
not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breastYes Class 1 - N t Pathoge ic/Low Clinical Significance-- 0.0044 0.0018
Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Breast_cancer|Hereditary_cancer-predisposing_syndrome|not_specified,Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndromeYes unknown 1 - Not p thogenic or of o clinical significance0.0033 0.0068
Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Familial_cancer_of_breast|Breast_cancer|Hereditary_cancer-predisposing_syndromeYes u known 1 - Not pathogenic or of o clinical significance0.0003 0
Hereditary_cancer-predisposing_syndrome|not_specified|Familial_cancer_of_breast-- -- 0.0013 0.0007
Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome,Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndromeYes unknown 1 - Not athogenic or of no clinical significance0.0005 0
Breast-ovarian_cancer,_familial_2|Familial_cancer_of_breast|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unknown 1 - Not pathogenic or of no clinical significance0 0
Familial_cancer_of_breast|not_specified|Hereditary_cancer-predisposing_syndrome-- -- 0.0097 0.0287
Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome,Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndromeYes not li ically imp rtant-- 0.0007 0.0002
Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndrome|Breast_cancerYes not li ically imp rtant-- 0.0004 0.0002
Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast,Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndromeYes u known -- 0 0
Fanconi_anemia-- -- 0.0046 0.0136
not_specified|Fanconi_anemia-- -- 0.0082 0.0239
not_specified|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- -- 0.0036 0.0011
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|not_specified|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn 1 - Not pathogenic or of no clinical significance0 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|not_specified|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn 1 - Not pathogenic or of no clinical significance0.0002 0.0002
not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|not_specified|Breast_cancer|Hereditary_cancer-predisposing_syndromeYes no  cli ically import t1 - Not pathogenic or of no clinical significance0.0011 0.0002
not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|not_specified|Breast_cancer|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome,Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2Yes no  cli ically import t-- 0.0033 0.0009
Hereditary_cancer-predisposing_syndrome|not_specified|Familial_cancer_of_breast-- -- 0.0014 0.0005
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn -- 0.0002 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn -- 0.0012 0.0036
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn -- 0.000077 0
Hereditary_cancer-predisposing_syndrome|Fanconi_anemia-- -- 0.001 0.0002
not_specified-- -- 0.0071 0.0207
not_specified-- -- 0.0007 0
not_specified-- -- 0 0
not_specified-- -- 0.0005 0.0002
not_specified-- -- 0 0
not_specified-- -- 0 0
not_specified-- -- 0.0009 0
not_specified-- -- 0.0008 0.0005
not_specified-- -- 0.002 0.0007
not_specified-- -- 0.0005 0.0014
not_specified-- -- 0.0031 0.0075
not_specified-- -- 0.0003 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2Yes unkn wn -- 0 0
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Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2,Breast-ovarian_cancer,_familial_2|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndromeYes unkn wn 1 - Not pathogenic or of no cli ical signific nce0.000077 0
not_specified|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- -- 0.0006 0.0007
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndromeYes unkn wn -- 0 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndromeYes unkn wn -- 0 0
Breast-ovarian_cancer,_familial_2|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome,Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unknown 1 - Not pathogenic or of no clinical significance0 0
Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_Breast_and_Ovarian_CancerYes Class 1 - Not Pathog nic/Low Clinical Significance-- 0.0016 0.0043
Breast-ovarian_cancer,_familial_2|not_provided|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|Hereditary_breast_and_ovarian_cancer_syndromeYes not cli ically important2 - Likely not pathogenic or of little clinical sig ificanc0.0015 0.0005
Breast-ovarian_cancer,_familial_2|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unknown -- 0 0
Breast-ovarian_cancer,_familial_2|Familial_cancer_of_breast|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome,Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndromeYes unknown 2 - Likely not path genic or of little clinical sig ificanc0 0
Familial_cancer_of_breast|Pancreatic_cancer_3|Hereditary_cancer-predisposing_syndrome|not_specified-- -- 0.0024 0.0009
Breast-ovarian_cancer,_familial_2|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specifiedYes unknown -- 0 0
Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- - 0.000077 0
Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- - 0.0002 0.0002
Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- - 0.0007 0.002
Breast-ovarian cancer, familial 2 | Hereditary breast and ovarian cancer syndrome | Hereditary cancer-predisposing syndromeYes Class 5 - Pathogenic5 - Defin tely pathogenic 0 0
Fanconi_anemia-- -- 0.000077 0
Fanconi_anemia,_complementation_group_C|not_provided-- -- 0.000077 0
Breast-ovarian_cancer,_familial_2|Familial_cancer_of_breast-- 5 - Definitely pathogenic 0 0
XERODERMA_PIGMENTOSUM,_TYPE_F|not_specified-- -- 0.0008 0.0002
Hereditary_cancer-predisposing_syndrome-- -- 0.000077 0
Familial_cancer_of_breast-- -- 0 0
Hereditary_cancer-predisposing_syndrome,Hereditary_cancer-predisposing_syndrome-- -- 0 0
Hereditary_cancer-predisposing_syndrome,Hereditary_cancer-predisposing_syndrome-- -- 0 0
Familial_cancer_of_breast,Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- -- 0 0
not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndrome|Breast_cancerYes no  cli ically import t-- 0.0015 0.0009
not_provided|Breast-ovarian_cancer,_familial_2|not_specified|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndromeYes unk own 1 - Not pathogenic or of no li ical signific nce0.0025 0.0009
Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_specified-- -- 0.0031 0.0023
not_provided|Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|not_specified|Hereditary_cancer-predisposing_syndromeYes unknown -- 0 0
Hereditary_cancer-predisposing_syndrome|not_specified|Familial_cancer_of_breast-- -- 0 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn -- 0 0
Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- - 0 0
Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast-- -- 0.000077 0
Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome-- - 0 0
Fanconi_anemia,_complementation_group_O|Hereditary_cancer-predisposing_syndrome-- -- 0 0
Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast-- -- 0.000077 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndromeYes unkn wn -- 0.000077 0
Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|not_providedYes unkn wn 2 - Likely not pathog n c or of littl  clinical significance0.000077 0
Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome,Hereditary_cancer-predisposing_syndrome-- -- 0 0
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2504 661 503 347
esp6500_ea 1000g2015aug_all 1000g2015aug_afr 1000g2015aug_eur
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
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0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0.0002 0.000199681 0 0.001
0 0 0 0
0 0 0 0
0 0 0 0
0.0009 0.000199681 0 0.001
0.0013 0.000199681 0 0.001
0.0008 0.000199681 0.0008 0
0.0013 0.000199681 0.0008 0
0.0003 0.000199681 0 0
0.003 0.000399361 0 0
0 0.00219649 0.0083 0
0 0 0 0
0.0012 0.000998403 0 0.003
0.0003 0 0 0
0 0.000199681 0 0.001
0 0.000199681 0 0.001
0.0001 0 0 0
0 0 0 0
0.001 0.000599042 0 0.003
0.0002 0 0 0
0 0.000199681 0 0
0 0 0 0
0 0 0 0
0.0003 0 0 0
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0.0026 0.000399361 0 0.002
0.0007 0 0 0
0 0.000199681 0 0
0.0001 0 0 0
0 0 0 0
0.0001 0 0 0
0.0001 0 0 0
0.0012 0 0 0
0.0001 0 0 0
0.0023 0 0 0
0.0001 0 0 0
0 0 0 0
0.0001 0 0 0
0.0006 0.000798722 0 0.004
0 0 0 0
0.0001 0 0 0
0.0001 0.000199681 0 0.001
0.0001 0 0 0
0.0007 0.000399361 0 0.002
0.0001 0.0181709 0.0681
0.0001 0.0185703 0.0696
0 0.000199681 0 0
0.0033 0.000798722 0 0.001
0.0001 0 0 0
0 0.000399361 0 0.001
0 0 0 0
0 0 0 0
0.0001 0 0 0
0 0 0 0
0.0003 0 0 0
0.002 0.000399361 0 0.002
0 0.00199681 0.0076 0
0 0 0 0
0 0 0 0
0 0.000199681 0.0008 0
0.0001 0.000199681 0 0
0.0001 0.000399361 0 0
0 0 0 0
0.0001 0.000199681 0 0.001
0.0001 0 0 0
0.0001 0 0 0
0.0002 0.000599042 0 0.001
0 0 0 0
0.0001 0.000199681 0 0
0.0002 0 0 0
0 0 0 0
0.0002 0.000199681 0.0008 0
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0 0.000199681 0 0
0.0031 0.00119808 0 0.005
0.0001 0 0 0
0 0 0 0
0.0003 0 0 0
0.0001 0 0 0
0 0.000199681 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0.00559105 0 0
0.0069 0.00259585 0.0008 0.0089
0.0057 0.00998403 0.0008 0.003
0.0015 0.00379393 0.0136 0.001
0.0005 0.000199681 0 0
0.0016 0.000399361 0 0.002
0.0008 0.00119808 0 0.004
0 0.000399361 0 0.002
0.0115815 0.0303
0.0009 0.000399361 0.0008 0.001
0.0005 0 0 0
0 0 0 0
0.00658946 0.0234
0.0001 0.00858626 0.031
0.0049 0.00159744 0 0.007
0 0 0 0
0.0002 0.000599042 0.0023 0
0.0015 0 0 0
0.0045 0.000599042 0 0.002
0.0019 0.000798722 0 0.001
0.0002 0 0 0
0 0.000998403 0.0038 0
0.0001 0 0 0
0.0014 0 0 0
0.0001 0.00978435 0.0287
0.001 0.00119808 0 0.002
0 0 0 0
0.0006 0.000199681 0 0.001
0 0 0 0
0 0.00519169 0 0
0.0014 0.000399361 0 0.002
0.001 0.000998403 0 0.003
0.0027 0 0 0
0.0001 0.0109824 0.0008 0
0.0008 0.00379393 0.0129 0.001
0.0005 0 0 0
0 0 0 0
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0.0001 0 0 0
0.0006 0 0 0
0 0 0 0
0 0.000199681 0.0008 0
0 0 0 0
0.0002 0.0159744 0.0023
0.002 0.000199681 0 0.001
0 0 0 0
0 0.000798722 0 0
0.0031 0.00119808 0 0.002
0 0 0 0
0.0001 0 0 0
0.0001 0.000199681 0 0
0 0 0 0
0 0 0 0
0.0001 0 0 0
0.0001 0 0 0
0 0 0 0
0.001 0 0 0
0.0001 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0.0017 0.000599042 0 0.003
0.0033 0.000798722 0.003
0.0035 0 0 0
0 0.000998403 0 0
0 0.00339457 0 0
0 0 0 0
0 0 0 0
0.0001 0 0 0
0 0.000599042 0 0
0 0 0 0
0.0001 0 0 0
0.0001 0 0 0
0.0001 0 0 0
0 0 0 0
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504 60706 5203 5789
1000g2015aug_amr 1000g2015aug_eas ExAC_nontcga_ALL ExAC_nontcga_AFR
0 0 0 0
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0 0 0 0
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0 0 0 0
0 0 0 0
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0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0.0002 0.0001
0 0 0.00006591 0
0 0 0.00001883 0.0001
0 0 0 0
0 0 0.0006204 0.0002237
0 0 0.0003 0
0 0 0.0009 0.0003
0 0 0.0012 0.0008
0.0014 0 0.0006 0.0001
0.0029 0 0.0015 0.0003
0 0 0.0004 0.0042
0 0 0.00002825 0
0.0029 0 0.0004 0
0 0 0.0001 0
0 0 0.0004 0
0 0 0.00003775 0
0 0 0.00003965 0
0 0 0.00008548 0
0 0 0.0022 0.0002
0 0 0 0
0.0014 0 0.0003 0.0035
0 0 0.00007535 0
0 0 0.00001905 0
0 0 0.0004 0.0002
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0 0 0.0015 0.0004
0 0 0.0002 0
0 0 0.00002825 0
0 0 0.000009466 0
0 0 0.0005 0
0 0 0.00005673 0
0 0 0.000009423 0
0 0 0.0009 0.0004
0 0 0.0001 0
0 0 0.001 0.0005
0 0 0.000009493 0
0 0 0.00006713 0
0 0 0.0001 0
0 0 0.0014 0.0001
0 0 0.00001887 0
0 0 0.00001883 0.0001
0 0 0.0000377 0
0 0 0.00001883 0
0 0 0.0005 0.0001
0.0014 0.005 0.0538
0.0014 0.005 0.0554
0 0.001 0.0002 0.0002
0.0029 0 0.002 0.0003
0 0 0.000009415 0
0 0 0.0001 0
0 0 0.00002825 0
0 0 0.00002825 0
0 0 0.00001256 0
0 0 0.0001 0
0 0 0.00008515 0
0 0 0.0009 0.0005
0 0 0.0007 0.0083
0 0 0.00002917 0
0 0 0.0001 0.0001
0 0 0.00003855 0.0002
0 0 0.0002 0
0 0 0.0007 0
0 0 0.0000754 0.0001
0 0 0.00001979 0
0 0 0.000009419 0
0 0 0.00001883 0
0 0 0.0006 0
0 0 0.00001883 0
0.0014 0 0.0002 0.0001
0 0 0.0002 0
0 0 0.0000471 0
0 0 0.0003 0.0007
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0 0.001 0 0
0.0014 0 0.0026 0.0009
0 0 0.00002828 0.0001
0 0 0.00001887 0
0 0 0.0002 0
0 0 0 0
0 0 0.00002831 0
0 0 0.0003 0
0 0 0.000009428 0
0 0 0.00001352 0
0.0014 0 0.0039 0.0001
0.0014 0 0.0043 0.0009
0.036 0.0083 0.001
0 0 0.0012 0.009
0.0014 0 0.0002 0.0002
0 0 0.0011 0.0003
0.0029 0 0.0006 0.0001
0 0 0.0003 0.0001
0.0014 0.0169 0.0035 0.0297
0 0 0.0005 0.0001
0 0 0.0004 0.0002
0 0 0.0003 0
0.0029 0.0017 0.0173
0.0029 0 0.02555
0.0014 0 0.0025 0.0017
0 0 0.00002885 0
0 0 0.0004 0.0002
0 0 0.0007 0.0001
0.0014 0 0.0019 0.0009
0.0014 0 0.0016 0.0003
0 0 0.00006678 0
0 0 0.0004 0.0031
0 0 0.00004724 0
0 0 0.0009 0.0003
0.0058 0.003 0.0031 0.024
0.0043 0 0.0009 0.0001
0 0 0.0001 0
0 0 0.0002 0.0001
0 0 0.00001012 0
0 0 0.0032 0
0 0 0.0005 0
0.0029 0 0.0005 0.0001
0 0 0.0013 0.0001
0 0 0.0059 0.0011
0.0014 0 0.0016 0.0131
0 0 0.0002 0.0001
0 0 0 0
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0 0 0.00000944 0
0 0 0.0004 0.0002
0 0 0 0
0 0 0.00002834 0.0001
0 0 0.0002 0
0.1066 0.003 0.0159 0.0023
0 0 0.0008 0.0006
0 0 0.000009702 0
0 0.004 0.0001 0
0.0058 0 0.0024 0.0004
0 0 0.00001899 0
0 0 0.0002 0
0.0014 0 0.0002 0
0 0 0.0002 0.0016
0 0 0 0
0 0 0 0
0 0 0.00000951 0
0 0 0 0
0 0 0.0004 0.0002
0 0 0.00001891 0
0 0 0.000009418 0
0 0 0 0
0 0 0.00001883 0
0 0 0 0
0 0 0.0024 0
0.0014 0.0016 0.0002
0 0 0.0018 0.0007
0 0 0.0005 0
0 0 0.0034 0.0001
0 0 0.00001939 0.0001
0 0 0.0000565 0
0 0 0.00004717 0
0 0.002 0.00002825 0
0 0 0.00004708 0
0 0 0.00002825 0
0 0 0.00004859 0
0 0 0.00001885 0
0 0 0 0
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Supplemental Table 4. Patients with rare variants in two or more different FA genes
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. Patients with rare variants in two or more different FA genes
alcohol (1=current; 2=former; 3-never) HPV Status (0 = Negative 1 = Positive)cancerSite ethnicity age
3 0 Oral Cavity W 38
1 -- Oropharynx W 45
1 -- Larynx A 49
1 -- Oropharynx H 43
3 -- Oropharynx W 40
3 0 Oral Cavity W 42
3 -- Oral Cavity A 31
3 -- Oropharynx W 44
1 0 Oropharynx W 46
3 0 Oral Cavity H 36
3 -- Larynx W 48
1 0 Oral Cavity H 36
3 -- Oral Cavity W 47
1 -- Oropharynx W 49
1 -- Oral Cavity W 36
1 -- Oral Cavity W 49
3 0 Oral Cavity W 43
2 1 Oropharynx H 42
Patient details







































































3 -- Larynx W 49
3 1 Oral Cavity A 49
1 1 Oropharynx W 47
3 -- Oral Cavity A 42
1 -- Oropharynx W 45
3 -- Oral Cavity A 46
1 1 Oropharynx W 45
1 1 Oral Cavity W 32
1 0 Oral Cavity W 49
3 -- Oral Cavity H 35
1 -- Oropharynx W 46
3 0 Oropharynx W 48
3 1 Oropharynx W 40
1 -- Oropharynx W 47
3 1 Larynx B 46
3 1 Oropharynx W 49
3 0 Oral Cavity W 49
2 -- Larynx W 41
2 -- Oropharynx W 48
0 -- Oral Cavity W 34
1 -- Oral Cavity W 41
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ageGroup sex chr start end ref alt gene cDNA
40less F 16 3642722 3642722 C G SLX4 c.2305G>C
14 45605551 45605551 A G FANCM c.317A>G
45-49 F 16 3639265 3639265 C A SLX4 c.4374G>T
16 89842176 89842176 C G FANCA c.1874G>C
45-49 M 13 32930598 32930598 T C BRCA2 c.7469T>C
17 59924572 59924572 G A BRIP1 c.517C>T
14 45658326 45658326 C T FANCM c.5101C>T
40-44 M 16 89816220 89816220 G A FANCA c.3157C>T
2 58387285 58387286 CT - FANCL c.1049_1050del
40-44 M 13 32929047 32929047 G C BRCA2 c.7057G>C
15 89825056 89825056 A G FANCI c.1573A>G
40-44 M 14 45605405 45605405 G C FANCM c.171G>C
16 89877157 89877157 C T FANCA c.480G>A
40less M 2 58390589 58390589 A C FANCL c.755T>G
9 35079445 35079445 T C FANCG c.77A>G
17 56780607 56780607 A G RAD51C c.622A>G
16 3644515 3644515 C T SLX4 c.2099G>A
40-44 M 16 3639991 3639991 C A SLX4 c.3648G>T
13 32911175 32911175 G A BRCA2 c.2683G>A
45-49 F 13 32893271 32893271 A G BRCA2 c.125A>G
16 23641406 23641406 T C PALB2 c.2069A>G
40less F 16 3647490 3647490 G A SLX4 c.1573C>T
17 59924572 59924572 G A BRIP1 c.517C>T
3 10107551 10107551 G C FANCD2 c.2273G>C
2 58386933 58386933 - AATT FANCL c.1094_1095insAATT
45-49 M 16 23647211 23647211 T C PALB2 c.656A>G
15 89811698 89811698 T C FANCI c.824T>C
16 3641280 3641280 C T SLX4 c.2359G>A
40less F 9 98011571 98011571 C T FANCC c.3G>A
16 89865628 89865628 G A FANCA c.839C>T
45-49 F 3 10070369 10070369 T C FANCD2 c.28T>C
16 3639378 3639378 T A SLX4 c.4261A>T
45-49 M 2 58386933 58386933 - AATT FANCL c.1094_1095insAATT
15 89811698 89811698 T C FANCI c.824T>C
40less M 17 59926512 59926512 C T BRIP1 c.485G>A
6 35426122 35426122 G C FANCE c.1018G>C
16 3647691 3647691 T C SLX4 c.1372A>G
45-49 M 15 89835982 89835982 C A FANCI c.2056C>A
9 97864005 97864005 A G FANCC c.1661T>C
40-44 F 13 32953550 32953550 G A BRCA2 c.8851G>A
17 59821830 59821830 C A BRIP1 c.2220G>T
40-44 M 3 10107587 10107587 A G FANCD2 c.2309A>G
15 89849316 89849316 C T FANCI c.3428C>T
Variant details
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45-49 M 16 14041578 14041578 G A ERCC4 c.2125G>A
15 89825056 89825056 A G FANCI c.1573A>G
45-49 M 13 32930598 32930598 T C BRCA2 c.7469T>C
3 10074646 10074646 G C FANCD2 c.195G>C
45-49 M 9 35075738 35075738 G T FANCG c.1157C>A
16 23646872 23646872 A T PALB2 c.995T>A
40-44 M 13 32913271 32913271 A C BRCA2 c.4779A>C
11 22646921 22646921 G C FANCF c.436C>G
45-49 M 14 45605405 45605405 G C FANCM c.171G>C
16 14029516 14029516 G C ERCC4 c.1727G>C
45-49 F 9 35074140 35074140 A G FANCG c.1834T>C
17 59870998 59870998 T C BRIP1 c.1433A>G
45-49 M 13 32954018 32954018 G A BRCA2 c.9085G>A
16 3640461 3640461 G A SLX4 c.3178C>T
40less M 16 89877386 89877386 G C FANCA c.377C>G
13 32945172 32945172 A C BRCA2 c.8567A>C
45-49 F 14 45605730 45605730 G A FANCM c.496G>A
16 3639378 3639378 T A SLX4 c.4261A>T
40less F 9 35077006 35077006 G T FANCG c.739C>A
14 45628478 45628478 C G FANCM c.1576C>G
45-49 M 14 45605405 45605405 G C FANCM c.171G>C
15 89825056 89825056 A G FANCI c.1573A>G
45-49 M 13 32900252 32900252 A G BRCA2 c.440A>G
16 23641186 23641186 C G PALB2 c.2289G>C
40-44 F 2 58386933 58386933 - AATT FANCL c.1094_1095insAATT
9 35075959 35075959 C G FANCG c.1143G>C
45-49 M 14 45645661 45645661 G T FANCM c.3704G>T
17 59885856 59885856 T C BRIP1 c.890A>G
45-49 M 14 45669125 45669127 GAG - FANCM c.6061_6063del
6 35424011 35424013 GGA - FANCE c.736_738del
45-49 F 13 32953550 32953550 G A BRCA2 c.8851G>A
16 23637715 23637715 G A PALB2 c.2590C>T
45-49 F 16 89877377 89877377 G A FANCA c.386C>T
16 14041570 14041570 T C ERCC4 c.2117T>C
40-44 M 16 89871709 89871709 C T FANCA c.688G>A
3 10085255 10085255 - TGGA FANCD2 c.1077_1078insTGGA
16 3640461 3640461 G A SLX4 c.3178C>T
45-49 F 13 32907407 32907407 A G BRCA2 c.1792A>G
17 59761303 59761303 C T BRIP1 c.3104G>A
40less M 13 32907407 32907407 A G BRCA2 c.1792A>G
17 56774172 56774172 G A RAD51C c.523G>A
40-44 M 17 59924505 59924505 A G BRIP1 c.584T>C
14 45605397 45605397 G A FANCM c.163G>A
16 3656645 3656645 A G SLX4 c.590T>C
Page 76 of 79Cancer











p.E769Q Benign unreported rare variants
p.N106S Damaging unreported rare variants
p.M1458I Benign novel
p.C625S Damaging unreported rare variants
p.I2490T Benign present in FAmutDB/ClinVar/BIC
p.R173C Damaging present in FAmutDB/ClinVar/BIC
p.Q1701X Damaging unreported rare variants
p.R1053C Benign unreported rare variants
p.Q355fs Damaging novel
p.G2353R Damaging present in FAmutDB/ClinVar/BIC
p.M525V Damaging unreported rare variants
p.L57F Benign unreported rare variants
p.M160I Benign present in FAmutDB/ClinVar/BIC
p.F257C Benign present in FAmutDB/ClinVar/BIC
p.Q26R Indeterminate present in FAmutDB/ClinVar/BIC
p.I208V Indeterminate unreported rare variants
p.G700E Damaging unreported rare variants
p.Q1216H Benign unreported rare variants
p.A895T Benign present in FAmutDB/ClinVar/BIC
p.Y42C Benign present in FAmutDB/ClinVar/BIC
p.Q690R Benign novel
p.R525C Benign unreported rare variants
p.R173C Damaging present in FAmutDB/ClinVar/BIC
p.C758S Damaging unreported rare variants
p.P370fs Damaging novel
p.D219G Benign present in FAmutDB/ClinVar/BIC
p.I275T Damaging unreported rare variants
p.E787K Indeterminate present in FAmutDB/ClinVar/BIC
p.M1I Damaging novel
p.A280V Damaging unreported rare variants
p.S10P Indeterminate unreported rare variants
p.I1421F Indeterminate present in FAmutDB/ClinVar/BIC
p.P370fs Damaging novel
p.I275T Damaging unreported rare variants
p.R162Q Damaging present in FAmutDB/ClinVar/BIC
p.G340R Indeterminate present in FAmutDB/ClinVar/BIC
p.K458E Damaging present in FAmutDB/ClinVar/BIC
p.Q686K Benign present in FAmutDB/ClinVar/BIC
p.L554P Damaging present in FAmutDB/ClinVar/BIC
p.A2951T Damaging present in FAmutDB/ClinVar/BIC
p.Q740H Damaging present in FAmutDB/ClinVar/BIC
p.K770R Benign unreported rare variants
p.T1143I Damaging unreported rare variants
Variant details
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p.V709M Damaging unreported rare variants
p.M525V Damaging unreported rare variants
p.I2490T Benign present in FAmutDB/ClinVar/BIC
p.Q65H Damaging present in FAmutDB/ClinVar/BIC
p.P386H Benign present in FAmutDB/ClinVar/BIC
p.L332H Indeterminate present in FAmutDB/ClinVar/BIC
p.E1593D Benign present in FAmutDB/ClinVar/BIC
p.L146V Damaging unreported rare variants
p.L57F Benign unreported rare variants
p.R576T Damaging present in FAmutDB/ClinVar/BIC
p.F612L Benign novel
p.H478R Indeterminate present in FAmutDB/ClinVar/BIC
p.A3029T Damaging present in FAmutDB/ClinVar/BIC
p.R1060W Indeterminate present in FAmutDB/ClinVar/BIC
p.T126R Benign unreported rare variants
p.E2856A Damaging present in FAmutDB/ClinVar/BIC
p.A166T Damaging unreported rare variants
p.I1421F Indeterminate present in FAmutDB/ClinVar/BIC
p.Q247K Damaging unreported rare variants
p.L526V Indeterminate unreported rare variants
p.L57F Benign unreported rare variants
p.M525V Damaging unreported rare variants
p.Q147R Benign present in FAmutDB/ClinVar/BIC
p.L763F Indeterminate present in FAmutDB/ClinVar/BIC
p.P370fs Damaging novel
p.R381S Indeterminate novel
p.G1235V Damaging unreported rare variants
p.K297R Indeterminate present in FAmutDB/ClinVar/BIC
p.2021_2021del Damaging novel
p.246_246del Damaging novel
p.A2951T Damaging present in FAmutDB/ClinVar/BIC
p.P864S Indeterminate present in FAmutDB/ClinVar/BIC
p.A129V Benign unreported rare variants
p.I706T Damaging present in FAmutDB/ClinVar/BIC
p.V230I Benign unreported rare variants
p.T359fs Damaging novel
p.R1060W Indeterminate present in FAmutDB/ClinVar/BIC
p.T598A Benign present in FAmutDB/ClinVar/BIC
p.R1035H Indeterminate present in FAmutDB/ClinVar/BIC
p.T598A Benign present in FAmutDB/ClinVar/BIC
p.A175T Damaging present in FAmutDB/ClinVar/BIC
p.L195P Benign present in FAmutDB/ClinVar/BIC
p.D55N Damaging unreported rare variants
p.V197A Benign present in FAmutDB/ClinVar/BIC
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leSupplemental Figure 1.  Enrolled patients under 50 years of age  with incident HNSCC and reason for exclusion from sequencing analysis. 
enrolled patients < 50yo 
N = 647 
patients with DNA available 
N = 468 
patients for sequencing 
N = 417 
No DNA available 
179 patients 
DNA poor quality 
51 patients 
149 oral cavity cancer 
230 oropharyngeal* cancer 
38 larynx** cancer 
*Includes 5 patients with upper neck lymph node metastasis with unidentified primary site. 
**Includes 3 patients with hypopharyngeal cancer. 
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